HORMONE EPIMERS REGULATE ER STRESS AND CORE REGULATORY GENES: NETWORK ANALYSIS WITH APPLICATIONS TO GLIOMA AND CHRONIC PRESSURE ULCERS by Shaak, Thomas L.
Virginia Commonwealth University 
VCU Scholars Compass 
Theses and Dissertations Graduate School 
2013 
HORMONE EPIMERS REGULATE ER STRESS AND CORE 
REGULATORY GENES: NETWORK ANALYSIS WITH APPLICATIONS 
TO GLIOMA AND CHRONIC PRESSURE ULCERS 
Thomas L. Shaak 
Virginia Commonwealth University 
Follow this and additional works at: https://scholarscompass.vcu.edu/etd 
 Part of the Life Sciences Commons 
 
© The Author 
Downloaded from 
https://scholarscompass.vcu.edu/etd/531 
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It 
has been accepted for inclusion in Theses and Dissertations by an authorized administrator of VCU Scholars 
Compass. For more information, please contact libcompass@vcu.edu. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©THOMAS L. SHAAK                           2013 
All Rights Reserved 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HORMONE EPIMERS REGULATE ER STRESS AND CORE REGULATORY GENES: 
NETWORK ANALYSIS WITH APPLICATIONS TO GLIOMA AND CHRONIC PRESSURE 
ULCERS 
 
 
A Dissertation submitted in partial fulfillment of the requirements for the degree Doctor of 
Philosophy at Virginia Commonwealth University 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
by 
 
 
THOMAS L. SHAAK, LtCol, USAF, BSC 
B.S. Microbiology, Pennsylvania State University, 1990 
M.S. Health Systems Administration, University of Medicine and Dentistry of New Jersey, 2003 
M.S. Integrated Life Science, Medical University of South Carolina, 2005 
 
 
Director: Dr. Robert F. Diegelmann, PhD., Professor of Biochemistry 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
 
August 2013
ACKNOWLEDGEMENT 
 
 
 
 
The author would like to thank several people and without them I do not think I would be here 
now. First, Dr. Douglas Wear, Dr. Mina Izadjoo, PhD.,  Dr. Sue Cross, PhD, Dr. Mohammed 
Alavi, PhD, Dr. Hyung Kim, DVM, PhD. all of whom inspired me when I thought I was beyond 
inspiration. Along that same line I would like to thank my sister Caren Butera, who provided an 
amazing amount of inspiration and support in many ways. Second, I would like to thank Dr. 
Robert F. Diegelmann and Dr. Kevin R. Ward for introducing me to a very special group of 
researchers who are involved in the cutting edge of science and medicine. I would like to make a 
special acknowledgement for Dr. Robert F. Diegelmann whose depth and breadth in wound 
healing is endless. I would like to thank him for accepting me into his lab, introducing me to 
many professional colleagues and pointing me in the right direction when I need it. I would also 
like to make a special acknowledgement to Dr. Roger M. Loria, his generosity in allowing me to 
work with the androstene hormones, tireless guidance and mentorship on all aspects of science, 
the many hours he spent discussing complex ideas have resulted in the best educational 
experience that I have ever had. I would like to thank the other members of my committee Dr. 
Danail Bonchev and Dr. John Ryan for guiding my project and introducing me to concepts which 
have enhanced my skills. I would also like to thank my parents Dr. Thomas A. Shaak, DDS and 
Mary A. Shaak for their support and for my kids, Jonathon and Katelyn who, have worked very 
hard on their programs at Texas A&M and made being father very easy and this work possible.  
 
 
 
 
 
 
ii 
 
TABLE OF CONTENTS 
 
 
 
 
LIST OF TABLES………………………………………………………………………..iv 
LIST OF FIGURES………………………………………………………………….……v 
LIST OFABBREVIATIONS………………………….………….…………………....vi 
ABSTRACT……………………………………………………………………..……viii 
CHAPTER 1: Introduction.……........…………………………………………………..1 
  Historical Perspective: Discovery of the anti-inflammatory effects of   
  corticosteroids..........................................................................................................1 
 
  Hypothalamus Pituitary Adrenal Axis………………………………………..….2 
  Dehydroepiandrosterone (DHEA)…………………………………….…………..3 
  Anticancer effects of DHEA……………………………………………………....4 
  Immune effects and DHEA….........………………………………..…………....5 
  Anti-autoimmune effects and DHEA…………...........…………………………6 
  Neural effects and DHEA……………………………..……………..…………6 
  DHEA, stress and the anti-glucocorticoid response………..……….…………...7 
  DHEA as a precursor to androstene hormones…………………………………....8 
   Δ5-androstene-3β, 17β-diol (17β-AED) and Δ5-androstene 3β, 17β-diol  
      (17βAET) Metabolism..............................................................................................9 
 
iii 
   
iii 
 
 
 
  DHEA, Δ5- androstene-3β, 17β-diol (17β-AED), Δ5- androstene-3β, 7β, 17β- 
  triol (17β-AET), immunity and antiglucocorticoid activity……………………...10 
 
Transcriptional Effects of 17β-AED and 17β-AET………………....….…..........12 
  DHEA, 17β-AED, 17β-AET and the estrogen/androgen Receptors……..…........14 
  Δ5-androstene-3β, 17α-diol (17α-AED)................................................................17 
Overview…………...…...………………………………………….....……22 
 CHAPTER 2: Structural Stereochemistry of Androstene Hormones Determines   
             Interactions with Human Androgen, Estrogen, and Glucocorticoid    
 Receptors….....……………………....…………………………............................24 
 
 Introduction……………………………………………………………………….24 
Methods………………………………………………………………………...25 
Nuclear Receptor Transactivation Assays………….......………………………...25 
Preparation of Stock Hormone Solutions………...………………………………26 
Mass Spectrometry………………………...……………………………………...27 
     Cellular Uptake of Androstene Hormones and Normalization of  
Transactivation Assay Results…...…………………........………………………..28 
 
Metabolism of Androstene Hormones…………………...………………………..28 
Statistical Analysis…………………………………………………………...…...29
Results and Discussion…………………..…..………….....…….………………29 
Androstene hormone structures………………..……............………………..…...29 
 Androstene Hormone Activation of the Human AR receptor…......…...….….…31 
      Androstene Hormone Activation of the human ERβ and ERα    
      Receptors…...….........……..…………………………………………...…………33 
 
      Androstene Hormone Activation of the Human Glucocorticoid (GR)  
 Receptor………………..........………………………………………..…………..36 
 
Summary…………………....…………………………………………………….42 
CHAPTER 3: Androstene Hormone Epimers Regulate ER Stress and  
Core Regulatory Genes in Human T98G Glioma Cells…………………..44 
 
Introduction………………………………………………………………………….44 
 
Methodology………………………………………………………………..……….51 
 
Cell culture……………………………………………………….………...………..51 
 
Androstene Hormone Controls……………………………………...………..……..51 
 
The Human Signal Transduction Pathway Finder Microarray…..………...………..51 
 
IPA Network Generation and Analysis…………………….......……………………54 
 
Network Generation…………......…………………………………………………..54 
 
Network Score Statistics………......…………………………………….…………..54 
 
Results and Discussion………………………..…………………………………….55 
 
The Human Signal Transduction Pathway Finder Microarray…..…....……………..55 
 
Network Analysis…………………………………...……………………..…………57 
 
Target Genes…………………...…………...............……………….……….……….57 
 
General Discussion…………………………….…………...….……………………..59 
iii 
 
Summary……………..……………………………………………………………..71 
 
CHAPTER 4: Pressure Ulcers in Patients with Spinal Cord Injury; Microarray and  
                       Network Analysis………………………………………….……………...73 
 
 Introduction……..…………………..…….…………………………...……...…....73 
Materials and Methods…….........……….………..………...……………………75 
Protection of Human Subjects….…………..…………………………………….75 
Recruitment and consent procedures.……..….………………………………..…75 
Specimens………………………..….….………………………………………..76 
Total RNA Extraction from Skin Tissues……..….…………….…………....……76 
Microarray analysis using Illumina Human-6 BeadChip arrays…..…...…………..77 
Microarray data analysis……………….………………………..………………..79 
Network Analysis………………...…………….…………..……………….........79 
Network Core Analysis………………………….…….....…………………...…..79 
Network Statistics (Score)…………….………….….....……………………..…..79 
Core regulator Analysis of Chronic Wounds…………….......…………...….….…..80 
Results and Discussion.……………....…………………………………….…..81 
Summary………………………………….............................................…………..100 
CHAPTER 5: General Discussion and Overall Conclusion............................................104 
REFERENCES……………………………………............................................……117 
APPENDIX 4A……………………………………………............................................142 
APPENDIX 4B................................................................................................................144 
iii 
 
 
APPENDIX 4C................................................................................................................146 
iii 
 
 
VITA………………………………………………………............................................147        
 
 
 LIST OF TABLES 
 
 
 
 
Table 1: Relative Androgenicity of Androstene Hormones…………………………...33 
Table 2: Relative Estrogenicity of Androstene Hormones……...………..……………….36 
Table 3: Biological Function of 17α-AED and 17β-AED…………………...…………..49 
Table 4: 17α-AED/17β-AED Target Genes in T98G Glioma Cells...........…......……..58 
Table 5: Whole Genome Microarray Network Analysis:  
Ubiquitin C-centered Networks...........................................................................78 
 
Table 6: Functions of Genes Associated with UBC in Normal Skin Controls and  
iv 
 
Chronic Pressure Ulcers of Spinal Cord Injury Patients…………...………....102 
  
 
LIST OF FIGURES 
 
 
 
 
Figure 1. The structures of the Androstene Hormones……………………...………............…...30 
Figure 2. Androstene Hormone Activation of the Human Androgen Receptor............................32 
Figure 3. Androstene Hormone Activation of the Human Estrogen Receptor Beta…..................34 
Figure 4. 17β-AED Activation of the Human Estrogen Receptor Alpha…………...............…...35 
Figure 5. Dexamethasone or Androstene Hormone Activation of the Human 
Glucocorticoid Receptor……............………………………….....…………………….37 
 
Figure 6. Androstene Hormones and Dexamethasone Activation of the Human GR 
Receptor………………………............………………...………………………………39 
 
Figure 7. Androstene Hormone and Dexamethasone Activation of the Human GR  
Receptor in the presence of Cyproterone Acetate………................…………………...41 
 
Figure 8. Contrasting Effects on Cell Morphology of T98Glioma cells  
treated with 17α-AED or 17β-AED………………………...............………………….46 
 
Figure 9: Structure-function relationship of the 17 hydroxyl position 
               of the chemically identical androstenediol epimers, 17α-AED and  
17β-AED results in opposing biological functions…...………................……………..47 
 
Figure 10: Human signal Transduction Pathway Finder Microarray….………...........………...53 
Figure 11: Contrasting Effects on Gene Expression in T98Glioma cells  
treated with 17α-AED or 17β-AED…………….............…………………………….56 
 
v 
 
Figure 12: General Mechanism of Autophagy Induction by 17α-AED.......................................60 
 Figure 13: Stress Induced Responses Directed by 17α-AED and 17β-AED……................…...63 
Figure 14: BRCA-1 directed, p53 dependent transcriptional response induced  
by 17β-AED…………………............……………………………………………….65 
 
Figure 15: Opposing Regulation of p53 Expression Induced by 17α-AED  
or 17β-AED through WNT1, AKT and GSK3β…………………...........………….66 
 
Figure 16: Core Regulatory Unit Governing Cell Cycle Arrest, Apoptosis,  
Inhibition of Angiogenesis and Metastasis and DNA Repair………............………..68 
 
Figure 17: T98G Gene Mutations in 3 Critical Glioblastoma Signaling Pathways…...............…72 
Figure 18: Network schematic of genes that are associated with UBC in the A) the   
normal skin network #1 or B) the chronic pressure ulcer network #1…............….…84 
 
Figure 19: UBAP1 Related Core Master Transcriptional Regulator Network……………….….88 
 
v 
 
 LIST OF ABBREVIATIONS 
 
 
 
 
vi 
 
 
(α) = alpha position 
 
17β-AED = Δ5-androstene-3β, 17β-diol 
 
17α-AED = Δ5-androstene-3β, 17α-diol  
 
17β-AET = Δ5-androstene-3β, 7β, 17β-triol 
Akt = v-akt murine thymoma viral oncogene homolog, protein kinase B 
Androstene Hormones = 17β-AED, 17α-AED, 17β-AET, DHEA 
Androstene Hormone Metabolites = 17β-AED, 17α-AED, 17β-AET 
 
AP-1 = Activating Protein 1  
 
AR = Androgen Receptor 
 
ARD = Ankyrin Repeat Domain  
 
ATF6 = Activating Transcription Factor 6 
 
(β) = beta position 
 
BCL2 = B-cell CLL/lymphoma 2  
 
BCR-ABL = Break Point Cluster Region Protein-Abelson  
 
Beclin-1 = beclin-1, autophagy related 
 vi 
 
 
 
BEX = Brain Expressed X-linked  
 
BIRC2 = baculoviral IAP repeat containing 2 
 
BMP2 = bone morphogenic protein 2 
 
BRCA1 = Breast Cancer 1 early onset 
 
CTSD = Cathepsin D 
 
C8orf76 = Chromosome 8 Open Reading Frame 76 
 
c-MYC = V-myc myelocyomatosis viral oncogenes homologue(Avian) 
 
CCL2 = Chemokine (C-C motif) ligand 2 
 
CDK2 = Cyclin-dependent kinase 2 
CDKN1A = Cyclin-dependent kinase inhibitor 1A (p21, Cip1) 
CDKN2D = Cyclin-dependent kinase inhibitor 2D (p19, inhibits CDK4) 
 
CERCAM = Cerebral endothelial cell adhesion Molecule 
CHOP = CCAAT/enhancer-binding protein homologous protein 
 
CPU = Chronic Pressure Ulcer  
 
CLIP3 = CAP-GLY domain containing linker protein 3 
 
ColGALT1 = Collagen Galactose Transferase 1 
 
ColGALT2 = Collagen Galactose  
 
CSN2 = Casein beta 
 
CYLD = Cylindromatosis tumor syndrome 
 
 vi 
 
 
CMV = Cytomegalovirus 
 
CtBP = C-terminal binding protein 1 
 
CtIP = Retinoblastoma binding protein 8 
 
DEF8 = Differentially Expressed in FDCP homologue (mouse) 
 
DHEA = Dehydroepiandrosterone 
 
DNA = Deoxyribonucleic Acid 
 
DUB = Deubiquinating enzyme 
 
DUSP-1 = Dual Specificity Phosphatase 1 
 
E1 = Ubiquitin Activating Enzyme 
 
E2 = Ubiquitin Conjugating Enzyme 
 
E3 = Ubiquitin E3 Ligase 
 
ELAVL1 = ELAV (embryonic lethal,abnormal vision, Drosophila)-like 1 
 
E2F = E2F transcription factor group 
 
EGFR = Epidermal Growth Factor Receptor  
 
ER = Endoplasmic Reticulum 
 
 vi 
 
 
ERα = Estrogen receptor alpha  
 
ERβ = Estrogen receptor beta 
 
ERAD = Endoplasmic Reticulum Associated Degradation 
 
ERN1 = Endoplasmic reticulum to nucleus signaling 1 
 
ESCRT1 = Endosomal Sorting Complexes Required for Transport 1 
 
ERK1/2 = Extracellular Signaling Related Kinase 1/2 
 
ESR1 = Estrogen Receptor Alpha 1 
 
FBA = Fbox associated protein  
 
FBX = Fbox 
 
FBXO = Fbox subfamily member 
 
GADD45A = Growth Arrest and DNA Damage Inducible Alpha 
 
GAPDH = Glyceraldehyde phosphate dehydrogenase 
 
GCR = Clucocorticoid receptor 
 
GPX = Glutathione peroxidase 
 
GR = glucocorticoid receptor 
 
GYS1 = Glycogen synthase 1 (muscle) 
 
GCN2 = General control non-derepressable 2 
 
GCR = Glucocorticoid receptor 
 
GERAD = Glycoprotein endoplasmic reticulum associated degradation 
 
 vi 
 
 
LMF2 = Lipase maturation factor 2 
 
MHC I = Major histocompatibility class 1 
 
MMGT1 = Membrane magnesium transporter 1 
 
NFKBIA = Nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor 
alpha 
 
mEMC = Mammalian ER membrane complex  
 
mRNP = Messenger ribonucleoprotein 
 
NAB2 = NGFI-A binding protein 2 (EGR-1 binding protein 2)  
 
NCCRP-1 = Nonspecific cytotoxic cell receptor protein-1 
 
ODC1 = Ornithine decarboxylase 1 
 
p300/CBP = E1A binding protein/p300/CREB Binding Protein 
 
P53 = Tumor protein 53 
 
PDGF = Platelet derived growth factor 
 
PERK = PRKR-like endoplasmic reticulum kinase 
 
PI3K = Phosphoinositide-3- kinase 
 
PI3KC3 = Phosphoinositide-3-kinase catalytic subunit type III 
 
PMEPAI =Prostate transmembrane protein-androgen induced 
PKR = Protein kinase, interferon-inducible double stranded RNA dependent activator 
 
Rb = Retinoblastoma protein 
 
RILPL1 = Rab interacting lysosomal 
 vi 
RIP1 = Receptor (TNFRSF)-interacting serine-threonine kinase 1 
 
RNA = Ribonucleic Acid 
 
RNF = Ring finger 
 
RNF24 = Ring finger protein 24 
 
RNF145 = Ring finger protein 145 
 
SECISBP2L = SECIS binding protein 2 homologue (S. cerevisiae)  
 
SCI = Spinal cord injury homologue (S. cerevisiae) 
 
SCF = Skp1, Cul1, Fbox and Rbx-1 
 
SECISBP2L = SECIS binding protein 2-like 
 
SIAH1 = Siah E3 ubiquitin ligase 1 
 
SIRT1 = Sirtuin 1 
 
SLC22A17 = Solute carrier family 22 
 
SWI-SNF = Switch/sucrose non-fermentable 
 
SQSTM1 = Sequestosome 1 
STAT1 = Signal transducer and activator of transcription 1, 91kDa 
 
Th1 = T helper Type 1 
 
Th2 = T helper Type  
 
THUMPD1 = THUMP domain containing 1 
 
TNFα = Tumor necrosis factor alpha  
 
 TNFRSF1 = Tumor necrosis factor receptor 1 
 
TP53I3 = tumor protein 53 inducible protein 3 
 
TRC8 = Ring finger protein 139 
 
TRPC = Transient receptor potential channel 
 
TsiL = T-cell secretion of interleukin 
 
TSG101 = Tumor susceptibility gene 101 
 
UBAP1 = Ubiquitin associated protein 1 
 
UBC = Ubiquitin C 
 
Vps28 = Vacuolar protein sorting 28  
Vps34 = Phosphatidylinositol 3-kinase, catalytic subunit type 3 
 
Vps37A = Vacuolar protein sorting 37A  
 
 
 
 
 
 
 
 
 
 
 
vi 
 
 ABSTRACT 
 
 
 
 
HORMONE EPIMERS REGULATE ER STRESS AND CORE REGULATORY GENES: 
NETWORK ANALYSIS WITH APPLICATIONS TO GLIOMA AND CHRONIC PRESSURE 
ULCERS 
 
 
THOMAS LEE SHAAK, PhD 
 
 
A Dissertation submitted in partial fulfillment  
of the requirements for the degree  
Doctor of Philosophy at  
Virginia Commonwealth University 
 
 
Virginia Commonwealth University, 2013 
 
 
Director: Dr. Robert F. Diegelmann, PhD., Professor of Biochemistry 
 
 
 
 
 
 
DHEA has been determined to have medically significant activity and is the parent compound to 
the more active metabolites; 17α-AED, 17β-AED and 17β-AET, which exhibit strong biological 
activity that has been attributed to androgenic, estrogenic or anti-glucocorticoid activity in vivo 
and in vitro. This study compared DHEA, 17α-AED, 17β-AED and 17β-AET for their ability to 
activate the human AR, ER and GR receptors and determine the relative androgenicity, 
estrogenicity and glucocorticoid activity. The results show that, at the receptor level, these 
androstene hormones are weak AR and even weaker ER activators.  Direct androstene hormone
  activation of the human AR, ERα, and ERβ may not be essential for their biological function. 
Similarly, these hormones indirectly activated the human GR receptor; only in the presence of 
high dexamethasone concentrations. These results underscore the major difference between 
androstene hormone interactions with these nuclear receptors.  
 17β-AED and 17α-AED, androstene epimers that produce either survival or death, were 
utilized to treat T98G Glioblastoma cells. We identified 26 genes oppositely regulated by 17β-
AED and 17α-AED to directly affect the cellular life or death decision. Network analysis 
demonstrated that these 26 genes are essential to regulating three critical Glioblastoma pathways. 
This report, for the first time, demonstrates that naturally occurring, chemically identical adrenal 
hormones (17β-AED or 17α-AED) direct a cellular life or death decision through contrasting 
modulation of identical signaling pathways and core regulators.  
 Chronic pressure ulcers represent a significant health problem and are characterized by 
hypoxia, bacterial infection, repetitive ischemia/reperfusion and altered cellular and systemic 
stress responses. Whole genome microarray analysis was utilized in conjunction with IPA® 
premiere networking software to analyze chronic wound edge tissue. IPA® network analysis 
identified Ubiquitin C (UBC) as the most significant network. Sixteen (16) ubiquitin C 
associated genes were identified to be different in the chronic pressure ulcer and normal skin 
control.  Targeted network analysis associated core regulators to 8 UBC associated genes that are 
unique to chronic pressure ulcers. The identification of these genes will allow the establishment 
of more effective treatments for Spinal Cord Injury (SCI) patients with chronic pressure ulcers. 
 
 
 CHAPTER 1: Introduction 
 
 
 
 
Historical Perspective: Discovery of the anti-inflammatory effects of corticosteroids 
 The effects of adrenal insufficiency was first discovered in 1855 by Thomas Addison [1]. 
In 1939, Butenandt received a Nobel Prize in chemistry for his work on steroid hormones and 
steroidogenesis [2]. This work and the work of others at this time period began the study of the 
steroid producing endocrine glands. Shortly thereafter, Kendall, Hench and Reichstein were 
awarded the Nobel Prize for the discovery of the anti-inflammatory effect of cortisol in 
rheumatoid arthritis patients marking the first time an endogenous hormone was discovered with 
significant anti-inflammatory effects [3].  This work sparked the clinical use of corticosteroids as 
long-term therapeutics for chronic inflammatory diseases. The beneficial effects of 
corticosteroids, however, was overshadowed by association with immune suppression and risk of 
infection, osteoporosis, thinning of the hair, stria formation, growth inhibition, hematopoietic 
abnormalities, psychological changes and delayed wound healing. Glucocorticoids administered 
in vivo impair activation of the immune system, increase pathological effects of disease and 
increase mortality to viral infections [4] 
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 Hypothalamus Pituitary Adrenal Axis 
 It has been know for more than 40 years that an immune response with elevated levels of 
circulating cytokines and activated immune cells can stimulate the HPA axis [5]. These 
observations were later confirmed in studies utilizing intravenous, intraperitoneal and 
intracerebroventricular cytokine studies [6-11]. ACTH stimulation will also increase the serum 
levels of adrenal hormones other than cortisol such as dehydroepiandrosterone and 
androstenedione [12][13]. These effects can be seen in patients with rheumatoid arthritis or who 
are undergoing surgery [14][15]. These reactions may include stimulation of peripheral sensory 
nerves [16][15]. Thus, it is not only cortisol but there are other adrenal steroids which are 
secreted after a short-term inflammatory stimulus. In this context, it has been demonstrated that 
high doses of IL-6 stimulate adrenocortical cells in vitro (92).  
 Chronic inflammatory diseases, however,  are associated with elevated levels of cortisol 
and decreased levels of DHEA while, as described above, acute elevations in inflammatory and 
immune cytokines increase DHEA and cortisol [17][18]. In long-term inflammatory disease 
there is a decreased responsiveness of the HPA axis during extended periods of inflammation 
where IL-6 or TNF serum levels are elevated [10]. Cortisol levels act rapidly on hypothalamic 
neurons to stop CRH releasing hormone [15]. Ultimately, longer-term elevated proinflammatory 
cytokines influence adrenal steroid hormone levels [19][20]. In addition, it was observed that 
there exists an age-related increase of serum IL-6 in healthy female and male subjects associating 
aging with reduced HPA responsiveness [21]. 
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 Dehydroepiandrosterone (DHEA) 
 Dehydroepiandrosterone (DHEA) and its sulfated derivative (DHEA-S) are the most 
abundant circulating steroid hormones in humans [22][23]. Despite large amounts of study, the 
molecular, cellular, physiological mechanisms of action remain elusive. DHEA is an adrenal 
cortical steroid classified as a neurosteroid which is present in high concentrations during 
gestation, and age related development [24]. DHEA has been classified as a neurosteroid because 
it can be synthesized de novo in the brain [25]. Additionally, astrocytes and neurons will convert 
pregnenolone to DHEA in the brain [26]. 
 The levels of DHEA peak during reproductive years and then decline dramatically with 
age [27]. DHEA is found to be regulated by the HPA in acute and chronic inflammatory 
situations.  DHEA, because of its biochemical, physiological, pharmacological, toxicological and 
clinical effects sparked intense scientific interest and a multitude of research efforts were 
undertaken and are currently ongoing to delineate the beneficial biological effects and action of 
DHEA.  
 DHEA has been intensely studied for its effects in treating cancer [28], viral and bacterial 
infection [29][30][350], auto-immune disease [31], arthritis [32], cardiovascular disease [33], 
control of body weight [34], stress [30][35], asbestosis [36], neural effects [37], diabetes 
(metabolic disease) [38], enzyme regulation [39], anti-oxidant effects [40], protection from 
ischemic/reperfusion [41], effects in bone metabolism [42], and an anti-glucocorticoid effect in 
promoting immune cell survival and proliferation [43]. DHEA is the parent hormone to its more 
active metabolites, however, the multitude and significance of the results obtained from DHEA 
are worth noting here for utility and perspective.   
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 Anticancer effects of DHEA 
 The effects of anti-carcinogenic effects of DHEA have been well studied. DHEA was 
shown to produce a decline in tumor burden in castrated mice with human prostate tumors that 
were propagated in nude mice [28]. Subsequently, fluorinated DHEA was studied because did 
not convert into estrogen and testosterone [44]. It was shown that 16 alpha-fluoro-5-androsten-
17-one, a non-androgenic DHEA analogue, significantly decreased the incidence of small 
intestinal tumors however, an increased dose was not as effective [45]. DHEA and 16 alpha-
fluoro-5-androsten-17-one reduced tumor initiation, tumor promoter-induced epidermal 
hyperplasia and promotion of papillomas in the two stage skin tumorigenesis model [46]. 
Together these observations suggested that DHEA alone has some anticancer effects although 
some activity may be attributed to its metabolites. 
 DHEA was found to reduce the incidence and multiplicity during both phases of 
mammary cancer and incidence was most affected by DHEA together with 4-HPR(n-(4-
hydroxyphenyl) retinamide) [47]. DHEA also delayed tumor development in p53 knockout mice 
[48]. DHEA also was associated with increased bone density and lowered serum triglyceride 
levels in rats with DMBA-induced mammary cancer [49]. Many more studies have associated 
DHEA with anti-cancer effects [50-53] to name a few. It must be noted that Hamilton et al. 
paradoxically found that DHEA actually increased colon tumor incidence when male F344 mice 
were fed 0.5% DHEA for 7 weeks beginning one day after the administration of azoxymethane 
[54]. 
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 Immune effects and DHEA 
  Multiple reports of the anti-viral effects of DHEA were reported in the 1990's. It was 
reported that DHEA administration to C57BL/6 mice infected with Murine retrovirus opposed 
retrovirus induced oxidative damage and loss of immune cytokines (IL-2, IFNγ) [55]. In these 
studies, DHEA opposed IL-6 and TNFα production by T helper 2 cells (TH2) and DHEA-S was 
found to oppose retrovirus induced T cell reduction in old mice. Subsequently, the effects of 
DHEA administration on lethal viral infections was studied and it was found that a single 
subcutaneous dose of DHEA was able to upregulate the immune response and provide protection 
against of lethal infective titers of  Herpes virus type 2 encephalitis or systemic Coxsackievirus 
B4 infection [56][350]. Subsequent studies demonstrated that DHEA/DHEA-S could provide 
significant benefits against immunodeficiency viruses by decreasing virus replication in vitro and 
provided protection against retrovirus-induced lipid peroxidation in the heart in vivo [57-59]. 
 The ability of DHEA to influence lipopolysaccharide (LPS)-induced TNFα and 
endotoxic shock was studied and the results demonstrated that DHEA significantly reduced the 
levels of LPS-induced TNFα and serum corticosterone levels which shows that DHEA is also 
influencing the stress response. The ability of DHEA to influence resuscitative trauma and the 
post-traumatic effect of LPS on the systemic inflammatory response was examined [60]. The 
results demonstrated that DHEA was insufficient in a pig model to protect against progressive 
shock and pulmonary failure at 4, 10 and 20 mg/kg doses administered at 1, 24, 48 and 72 hours 
after trauma. 
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 Anti-autoimmune effects and DHEA 
 It was discovered that 200mg/day of DHEA decreased systemic lupus erythematosus 
(SLE) activity [61]. Later clinical studies by this same group demonstrated that DHEA treatment 
alleviated SLE symptoms and systemic manifestations [31]. Subsequently, cytokine studies 
demonstrated that DHEA levels were found to be low in SLE patients and that DHEA 
upregulated IL-2 production of normal T cells and reversed the effects of SLE in these patients 
[62][63]. These results prompted suggestions that low levels of DHEA may be responsible for 
defects in IL-2 synthesis [62]. Additionally, it was reported that DHEA also reduced the 
incidence and severity of collagen-induced arthritis [32]. DHEA-S was subsequently shown to be 
increased after TNFα inhibition in rheumatoid arthritis patients [64]. Together, these results 
strongly suggest that low DHEA in conjuction with TNFα levels underlie these diseases. 
 
Neural effects and DHEA 
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 It was discovered that DHEA (500mg) given orally to normal subjects induced significant 
increases in rapid eye movement (REM) sleep during the first 2 hour sleep period [65]. These 
studies demonstrated that DHEA had  different effects at different stages of sleep suggesting that 
DHEA had a mixed GABA-A agonist/antagonist response [65].  DHEA, administered 
intracerebroventricularly, was found to improve memory and it was postulated that DHEA 
converged as a transcription facilitator for immediate -memory functional genes[66]. Another 
group discovered that DHEA administration over 18 months resulted in counteracting the age-
induced suppression of CRH mRNA levels in the hypothalamic periventricular nucleus of both 
sexes [67]. Additionally, it was found that the decline in DHEA levels in aged people may be 
 related to pathological amyloid precursor protein metabolism[68]. These results strongly 
demonstrate a link between the HPA axis, low DHEA and age-related dementia.  
 
DHEA, stress and the anti-glucocorticoid Response 
 In an elegant experiment, it was shown that mice inoculated with West Nile Virus and 
subjected to cold stress followed by serial injection with DHEA(10-20 mg/kg) were protected 
from viral infection in the blood, brain and lymphoid organs [30] providing additional support 
that DHEA is an anti-stress agent. DHEA was also utilized to treat high and low anxiety in rats 
and it was reported that DHEA significantly decreased behavioral despair associated with high 
anxiety while there was no significant effects noted in rats with low anxiety [35]. DHEA was 
also administered to sound stressed male Sprague-Dawley rats and it was noted that DHEA 
blocked the stress induced tryptophan hydroxylase activity in the mid-brain and cortex regions of 
the brain [69]. In these experiments DHEA was administered in conjunction with estrogen, 
progesterone, testosterone and a glucocorticoid agonist and found that estrogen, testosterone and 
progesterone had no effect in blocking sound stress induced tryptophan hydroxylase activity 
while DHEA alone or in combination with the glucocorticoid inhibitor blocked sound stress.  
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 Tryptophan hydroxylase is an enzyme that is increased by glucocorticoids and limits the 
production of 5-hydroxytryptamine the ligand of the serotonin receptors [70].  Furthermore these 
receptors are responsible for modulating and releasing multiple neurotransmitters including 
GABA [71]. Glucocorticoid activity (RU 28362) did not increase the sound stress-induced 
production of tryptophan hydroxylase in the presence of DHEA and it was suggested that DHEA 
achieved this activity through antiglucocorticoid action [69]. It was discovered that high dose 
 DHEA pretreatment antagonized dexamethasone-induced thymic and splenic atrophy at 60 
mg/kg while low doses (10-7 to 10-8 M) did not provide protection [43].  
 In addition, it was reported that DHEA alone would not block tyrosine aminotransferase 
(a glucocorticoid induced enzyme), however DHEA in the presence of dexamethasone blocked 
dexamethasone induced suppression of tyrosine aminotransferase and ornithine decarboxylase in 
a time and dose dependent fashion demonstrating the DHEA association with glucocorticoid 
transcribed genes [72][73]. Studies on the effects of DHEA on levels of the glucocorticoid 
receptor demonstrated that levels of the glucocorticoid receptor were significantly reduced by 
DHEA [74]. Together, these observations demonstrate that complex interactions are occurring 
that involve DHEA, the glucocorticoid receptor and influence the transcriptional responses 
affecting immune responses, cancer and stress.   
 
DHEA as a precursor to androstene hormones 
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 The effects of DHEA have commonly been performed in animal models. DHEA 
administered as a food admixture resulted in female rats obtaining plasma levels of DHEA that 
were an order higher than that of the male rats [75][76]. Tissue distribution of DHEA was 
subsequently studied in male and female Sprague-Dawley rats following oral administration and 
it was observed that there were no main sex differences between male and female rats[74]. 
DHEA levels rapidly decreased within 24 hours and was found to be primarily retained mainly in 
the liver, kidney, pituitary and bone marrow [74]. The presence of radioactive DHEA was 
observed in the pituitary and bone marrow even when levels of radioactivity were significantly 
decreased [74]. 
  A significant difference in DHEA excretion was found to exist between males and 
females. Male rats excrete DHEA in the faeces while female rats excrete DHEA metabolites in 
the urine [74]. Both sexes excrete the DHEA metabolites in the first 24 hours after ingestion 
[74]. While sex differences in excretion exist between serum, urine, bile, liver and faeces, the 
metabolite that was found to be present in the greatest concentration was Δ5-androstene-3β, 17β-
diol (17β-AED) in female rats and more polar DHEA metabolites including Δ5-androstene-3β, 
17β-diol (17β-AED) in males [74]. The presence of polar metabolites to dominate demonstrated 
that these metabolites may have significance. It was observed that DHEA is only found in trace 
amounts after administration and excreted polar metabolites with a hydroxyl group in the 7 
position were present.  Importantly, 7-hydoxylated steroids had been observed to have an 
important role in the immune stimulation of mice [77][78]. Thus, in addition to DHEA, 
considerable attention has been given to the study of 17β-AED, and Δ5-androstene-3β, 17β-triol 
(17β-AET). 
 
Δ5-androstene-3β, 17β-diol (17β-AED) and Δ5- androstene 3β, 17β-diol (17β-AET) Metabolism 
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  Δ5-androstene-3β, 17β-diol (17β-AED) is one of the primary metabolites derived from 
DHEA. 17β-AED is a derivative of DHEA which results from conversion of the keto group to 
a hydroxyl group at the 17 position [74].  17β-AED is hydroxylated at the 7 position before Δ5-
androstene-3β, 17β-triol (17β-AET) can be formed [79]. The biological activity of DHEA, 17β-
AED, 17β-AET has been demonstrated to occur through the subcutaneous route [80][81]. The 
skin, in turn, has been shown to contain all the necessary enzymes to convert DHEA to 17β-AED 
and 17β-AET [82-85]. 17β-AED metabolism has been evaluated in men and women and it has 
been found circulating in the serum [86][87]. Metabolism of Δ5-androstene-3β, 17β-diol (17β-
 AED) was evaluated and found to be comparable in men and women and was converted into 
DHEA, 17β-AED sulfate and DHEA-S [87]. An important observation is that DHEA can be 
transformed into 17β-AED and conversely, 17β-AED can be transformed back to DHEA 
[74][87]. This indicates that some interconversion can occur which may be related to DHEA or 
17β-AED functionality where this interconversion occurs.  
 
DHEA, Δ5- androstene-3β, 17β-diol (17β-AED), Δ5- androstene-3β, 7β, 17β-triol (17β-AET), 
immunity and antiglucocorticoid activity 
 Δ5-androstene-3β, 17β-diol (17β-AED) is a DHEA metabolite that possesses 
considerable ability to upregulate immunity in a generalized and non-specific fashion [88]. It was 
determined that DHEA was not the active agent that induced the host immune response [80]. 
Consequently, it was shown that 17β-AED, at 1/3 the dose of DHEA, is at least 100 times more 
effective than DHEA at increasing host immunity needed to protect against many different types 
of infection including viral, bacterial, parasitic and non-infectious agents [90]. 17β-AET 
possesses 10,000 times the efficacy of inducing the host immune response than is DHEA [89].  
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 17β-AED was tested in vivo to determine the most effective route of administration and 
effective dosage [91]. It was shown that 17β-AED, by the cutaneous route, would protect against 
lethal infection at 20, 80 or 160 mg/kg doses, however, it was determined that only 320 mg/kg 
17β-AED only in the presence of an antigen would induce spleen and thymus proliferation [91]. 
This is in contrast to DHEA which did not induce spleen or thymus proliferation [91]. In these 
studies, heart destruction by coxsackie virus-induced cytotoxic lymphocytic activity was noted to 
be absent when 17β-AED was present thus demonstrating that host cytotoxic lymphocyte 
activity was inhibited even in the presence of the infecting virus indicating that a non-
 glucocorticoid, anti-inflammatory action could be achieved through host immune modulation 
[91]. 
 DHEA and 17β-AED were studied for their ability to protect mice against lethal bacterial 
infection and LPS toxicity [88]. 17β-AED was shown to have no effect on TNFα levels that was 
induced to an in vivo LPS challenge in mice [88]. In opposition and similarly to glucocorticoids , 
DHEA inhibited TNFα concentration in these studies [29][88]. Furthermore, in vitro experiments 
with RAW 264.7 macrophages demonstrated the same effects that were seen in vivo[88]. 
 In addition to DHEA and 17β-AED, Δ5-androstene-3β, 7β, 17β-triol (17β-AET ) was 
synthesized and found to be even more potent than 17β-AED in upregulating the immune 
response in vivo [81]. 17β-AET was also found to possess anti-glucocorticoid activity [92]. 
Mitogen treated spleen cells were exposed to 17β-AET, 17β-AED and DHEA and it was 
reported that 17β-AET increased IL-2 and IL-3 while 17β-AED had no effect and DHEA 
decreased the levels of these two cytokines that are suppressed by glucocorticoids [92]. Because 
17β-AED and 17β-AET were effective in upregulating host immunity in vivo and displayed anti-
glucocorticoid activity that was different from DHEA and each other, further studies were 
pursued to further examine the anti-glucocorticoid effects on immune mediating macrophages 
and lymphocytes. 
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  Studies were performed with DHEA and 17β-AED on the ability of these androstene 
hormones to counteract the action of glucocorticoids on macrophages and lymphocytes in vitro 
[93][78].  Glucocorticoids have been reported to downregulate TNFα, IL-1, and IL-6 [94-96]. In 
LPS stimulated RAW264.7 macrophages, 17β-AET increased IL-1 and TNFα, 17β-AED did not 
affect IL-1 or TNFα, while DHEA decreased both IL-1 and TNFα [97]. Strikingly, all three 
androstene hormones decreased IL-6 to the same level as hydrocortisone in these cells [93]. In 
 mitogen stimulated lymphocytes a similar pattern was noted for IL-2 and IL-3 suppression by 
hydrocortisone where 17β-AET in the presence of hydrocortisone significantly increased IL-2 
and IL-3, 17β-AED increased IL-2 and IL-3 at high concentrations to levels lower than 17β-
AET, while DHEA maintained levels of IL-2 and IL-3 at the same level as the hydrocortisone 
control [78]. Together, these results demonstrate that immune mediating macrophages and 
lymphocytes respond differentially to DHEA, 17β-AED and 17β-AET and display an increasing 
anti-glucocorticoid and immune functionality from DHEA to 17β-AED to 17β-AET.  
 Together, these results demonstrate that DHEA, 17β-AED and 17β-AET differentially 
regulate immune responses in vivo and in vitro and also possess differential activity with 
glucocorticoids. Because DHEA, 17β-AED and 17β-AET possess different anti-glucocorticoid 
activity in vivo and in vitro then open questions are 1) Do they each interact with the 
glucocorticoid receptor differently at the level of the glucocorticoid receptor? and 2) Do they 
each interact with the glucocorticoid receptor at all? 
 
Transcriptional Effects of 17β-AED and 17β-AET 
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 DHEA, 17β-AED and 17β-AET possess different anti-glucocorticoid activity in vivo and 
in vitro. Glucocorticoids and gamma irradiation both induce immune injury. Glucocorticoids 
cause destruction of lymphoid cells and alters RNA synthesis [4]. Gamma irradiation damages 
genetic material in all blood components and mediates destruction of lymphocytes[98]. Thus, 
and 17β-AET were evaluated on their ability to counteract the damaging effects of whole body 
ionizing radiation [99-101]. It was discovered that not only did 17β-AED and 17β-AET protect 
against a lethal radiation dose of 8Gy(800 rad) at subcutaneously administered concentrations of 
320 mg/kg for 17β-AED and 30 mg/kg for 17β-AET but also increased immune protection 
 against Coxsackie B4 virus as they did with unirradiated animals [81]. Together, these results 
demonstrate that both 17β-AED and 17β-AET produce survival against the damaging and 
destructive effects of lethal irradiation and at the same time restore the immune effects.  
 Ultimately, it was discovered that 17β-AED stimulated protection and accelerated multi-
lineage blood cell  recovery and elevated bone marrow (BM) cellularity [101]. Spleen colony-
forming unit assays showed that combined treatment with 5-AED plus thrombopoietin resulted 
in a 3 to 4 fold increase as opposed to 5-AED and TPO alone [101]. In opposition to 
thrombopoietin, 17β-AED demonstrated protection and survival of bone marrow progenitors 
[100] [101]. These studies identified transcription factors and cytokines present in the response 
to irradiation 17β-AED was associated with elevation of GM-CSF, IL-2, IL-3, IL-6 and IL-10 in 
the spleen before irradiation and GM-CSF, IL-2 in bone marrow. Post-irradiation G-CSF, GM-
CSF, Interferon gamma, thrombopoietin, IL-2, IL-3, IL-6, IL-10 and IL-12 were all elevated in 
spleen and GM-CSF,  interferon gamma, thrombopoietin, IL-3 and IL-10 in bone marrow [102] 
Expression of G-CSF was associated with the master transcriptional regulator: NFkB1 in 
response to irradiation [100][103]. Because increased levels of CDKN1A, BCL2, BAX and 
DDB1 were observed, 17β-AED was associated with cellular programs of DNA damage 
prevention, cell cycle progression and apoptosis. These results demonstrate that 17β-AED, 
through a program distinct from thrombopoietin, will direct the expression of cytokines in 
response to irradiation and suggest that these cytokines are the result of a transcriptional program 
inclusive of NFkB1. 
13 
 17β-AED and 17β-AET possess different anti-glucocorticoid activity in vivo and in vitro 
and demonstrated ability to direct transcriptional programs that result in survival in response to 
stress.  17β-AED and 17β-AET were subsequently tested for their ability to improve otherwise 
 depressed cardiac function and cytokines after trauma hemorrhage [104]. It was observed that 
17β-AED significantly improved blood flow in the liver, brain, kidney, pancreas, spleen and 
adrenal glands, significantly reduced IL-6, and raised nitrates/nitrites [104]. It was also reported 
that 17β-AED improved hepatic portal function through decreasing endothelin-1 and increasing 
eNOS [105]. 
 Subsequently, it was reported that peroxisome proliferator activated-receptor gamma 
(PPARγ) was at least, in part, responsible for the beneficial decrease in IL-6 and iNOS [106]. 
17β-AET also was found to provide protection against trauma hemorrhage and it was reported 
that 17β-AET decreased IL-6 while increasing IL-2 and IFNγ in the spleen [107][108]. Together 
these observations demonstrate that 17β-AED and 17β-AET induction of transcriptional 
programs resulting in survival that are at least, in part, mediated by transcriptional master 
regulators (PPARγ).  
 17β-AED possesses anti-glucocorticoid activity in vivo and in vitro. Stress and the 
glucocorticoid receptor (GCR) are known to delay wound healing [109-112]. Blockade of the 
GCR increased IL-1β and keratinocyte growth factor 1 KGF-1 levels in these studies and 
increased wound cellularity and returned wound healing to normal [109]. Similarly, 17β-AED 
reversed glucocorticoid suppression of IL-1β and PDGF [112]. 17β-AED thus appears to also 
affect gene expression patterns in cutaneous wounds through the GCR transcriptional regulator. 
 
DHEA, 17β-AED, 17β-AET and the estrogen/androgen receptors 
14 
 Estrogen and Androgen are master transcription regulators that are members of the 
nuclear receptor superfamily [113]. Cutaneous wound healing and neuroprotective activity has 
generally been attributed to estrogen derived from DHEA [26][114-116].  Subsequently, it has 
 been demonstrated that cutaneous wound healing is associated with the action of the estrogen 
receptor beta (ERβ) and that androgen opposed the action of ERβ [117]. 17β-AED has inherent 
androgenic and estrogenic properties [118-120]. Furthermore, studies of trauma-hemorrhage 
have associated increased NFkB and activator protein-1 (AP-1) with increased IL-6 and TNFα 
[121]. Normalization of all these proteins was obtained by 17β-estradiol and was associated with 
PPARγ [121]. These observations have led some to hypothesize that androstene hormones may 
function similarly to estrogen [122]. 
 It has been known for some time that 17β-AED possesses both androgenic and estrogenic 
activity [123]. Several studies demonstrate the activation of the estrogen and androgen receptor 
by C19 steroids with resultant "estrogenic effects" (i.e. gain in uterine weight) "androgenic 
effects" (i.e. hirsutism), or proliferation of human mammary cancer cells [124-130]. A "google 
scholar" search of "estrogen and proliferation" returned 685,000 results while the same search 
with androgen yielded 163,000 results. Clearly, androgen and estrogen are associated with 
proliferation. It was noted that 17β-AED was present in high concentrations in some 
proliferative diseases, mainly breast cancer [131] and prostate cancer [132]. Some studies 
reported that androgenic metabolites may compete with 17β-estradiol and translocated the 
estrogen receptor in the uterus and mammary tumors [133-137]. Thus, it was thought that 17β-
AED, either itself or as a metabolite, was responsible for cellular proliferation through an 
interaction with either the androgen or estrogen receptor.  
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 It was found that in mammary cancer, estrogen stimulated MCF-1, ZR-75, T47-D and 
EFM-19 cells [138-141]. It was reported that high concentrations of androgen enhanced growth 
of EFM-19 and MCF-7 [141][142] cells while physiological concentrations of androgen were 
inhibitory in ZR-75-1 and MFM-223 cells[143][144]. Estrogen and androgen receptors were 
 present and found in different concentrations in all of these cell lines [144]. Subsequently, 17β-
AED was tested on MFM-223 (high androgen receptors and low estrogen receptors) and MCF-7 
(low androgen receptors and high estrogen receptors) breast cancer cells [145]. 17β-AED was 
found to be inhibitory in the MFM-223 cells and growth promoting in MCF-7 cells [145]. These 
studies demonstrated that it took 3 orders of magnitude greater concentration of 17β-AED to 
cause the proliferative effect in conjunction with the estrogen receptor while the  inhibitory effect 
of 17β-AED on MFM-223 cells was only partially reversed through cyproterone acetate [145].   
 It has been shown through structural modeling of the estrogen receptor alpha binding 
pocket that this receptor can accommodate many molecules including 17β-AED [146]. 
Additionally, it is mentioned that Δ5-steroids, including 17β-AED, may be ancestral ligands of 
the estrogen receptor [146]. Interestingly, because the estrogen receptor is believed to have 
undergone convergent evolution this may imply a different functionality for 17β-AED [147]. 
These results demonstrate that indeed 17β-AED may compete with 17β-estradiol and affect its 
structure and function. 
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 These results demonstrate that 17β-AED interacts differently than either estrogen or 
testosterone and that the biological effects are dictated by the composition of the cells. Since, 
there can be opposing effects within the same cell type; it is unclear the effects of DHEA are due 
strictly to the estrogen and androgen receptors. Recently, it was shown that 17β-AED is anti-
inflammatory in a model of experimental autoimmune encephalitis [148]. It was shown that 17β-
AED and not 17β-estradiol inhibited lipopolysaccharide induced IL-6 through a mechanism that 
involved 17β-AED binding the estrogen receptor beta along with the recruitment of CtBP to 
tether and suppress the activity of cFos [148] . This suppressive action of 17β-AED is clearly 
different than the actions of 17β-estradiol on the estrogen receptor.  
  17β-AED was shown to mechanistically interact with cFos and influence IL-6 differently 
than 17β-estradiol [148]. These observations further implicate the 17β-AED influence of gene 
expression in the presence of inflammatory stimuli through another master transcriptional 
regulator (cFos), in addition to those already discussed (NFkB and PPAR). Thus, the 
transcription factors that have been studied and reported for DHEA and 17β-AED so far 
resemble the same transcription factors reported for 17β-estradiol. The biological actions and 
mechanistic effects, however, are clearly different. Together, the differences in the immune 
regulation and in anti-glucocorticoid activity attributed to DHEA, 17β-AED and 17β-AET 
indicate that these receptors may have different interactions at the level of the ER and AR 
receptors. 
 
Δ5-androstene-3β, 17α-diol (17α-AED) 
  17β-AED and 17α-AED are chemically identical and the only difference is the position of 
the hydroxyl group at the 17-position [149]. 17β-AED is derived from DHEA. 17α-AED is 
another C19 Δ5-steroid that, like 17β-AED is produced in the testes[150][151].  17α-AED is 
found in the amniotic fluid and fetal-placental circulation during pregnancy with the ratio of 17α-
AED to 17β-AED of 9:1 in favor of 17α-AED. In adulthood the ratio is 2:1 in favor of 17β-AED 
[150][151]. 17α-AED and 17β-AED have been associated with epitestosterone production in the 
human testes [152]. Additionally, while it has not been confirmed, 17β-AED and epitestosterone 
have been shown to be formed in the human ovarian follicular fluid [153]. Low levels of 17α-
AED have been associated with toxemia, diabetes and placental insufficiency [152].  
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 17α-AED was originally tested for biological activity on myeloid oncogenic cell lines 
[154]. It was reported that 17α-AED had an anti-proliferative effect on murine macrophage 264.7 
 macrophages, murine p388D1 lymphoid neoplasm cells, human promyelocytic leukemia (HL-
60) cells demonstrating an anti-proliferative effect across three different types of myeloid cell 
types [154]. Additionally, 17α-AED at 50 nM was shown to produce irreversible apoptosis 
shown by electron microscopy in 2 (HL-60 and Raw 364.7) of the 3 cell lines while 17β-AED, 
the epimer of 17α-AED, at the same concentration did not produce cell death.  
 HL-60 cells were treated with either 17β-AED or 17α-AED and it was discovered that 
17β-AED at all concentrations promoted incorporation of [3H] thymidine and thus demonstrated 
DNA synthesis as opposed to 17α-AED which at concentrations at or above 12.5 nM  didn't 
promote [3H] thymidine uptake [154]. The [3H] thymidine uptake test was also performed for 
Raw 264.7 cells and it was demonstrated that [3H] thymidine uptake was inhibited at 17α-AED 
concentrations at or above 50 nM and, in this cell line, 17β-AED produced a decrease in the [3H] 
thymidine uptake at levels at or above 500 nM [154]. In the p388D1 lymphoid cells, 17α-AED 
produced a significant reduction in [3H] thymidine uptake and produced an anti-proliferative 
effect at concentrations at or above 12.25 nM while 17β-AED did not decrease DNA synthesis at 
any concentration [154]. Together, these results show that DNA synthesis correlated with an 
anti-proliferative effect for 17α-AED and a proliferative effect for 17β-AED in these myeloid 
cells lines. 
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 Because anti-proliferative effects were demonstrated by 17α-AED on the myeloid cell 
lines this epimer of 17β-AED was tested for anti-proliferative ability in the ZR75-1 (estrogen 
positive) and MDA-MB231 (estrogen negative) human mammary cancer cell lines [155]. 
Because the chemically identical epimer, 17β-AED, is produced in primary breast tumors [156] 
and 17β-AED is known to possess an ability to interact with the estrogen and androgen receptors 
[119], these tests were performed in the ZR75-1  and MDA-MB231 cell lines. 
   The results demonstrated that similar to myeloid cells, 17α-AED inhibited proliferation 
of ZR75-1 and MDA-MB231 cells between the concentration of 12.5 to 50 nM [155]. These 
studies were repeated with flutamide blocked androgen receptors and no change was noted in the 
anti-proliferative ability of 17α-AED on both cell lines [155]. 17α-AED was tested 
simultaneously with 17β-estradiol on the ZR75-1 cells and an enhanced anti-proliferative effect 
was noted [155]. 17β-AED and 17α-AED were tested simultaneously on ZR75-1 cells and a 
profound decrease in proliferation was noted [155]. 
 It was shown in separate experiments with the estrogen inhibitor, tamoxifen and the 
androgen inhibitor flutamide that 17β-AED appeared to have anti-proliferative effects on MCF-7 
cells(androgen and estrogen receptor positive) through the androgen receptor and proliferative 
effects through the estrogen receptor. Together, these studies associate 17β-AED with estrogen 
and androgen activity, which was shown to be dependent on the receptor content and "growth 
properties" of the cells [119] and that 17α-AED will oppose these activities independent of the 
androgen and estrogen receptors. 
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 17α-AED produced anti-proliferative effects in different cell lines. DHEA, 17β-AED, 
17β-AET and 17α-AED are derived from neural tissue. With 17α-AED producing anti-
proliferative, and in most cases cell death, these hormones were tested for cytotoxic ability on 
T98G Glioblastoma and U937 Lymphoma cells [157]. 17α-AED produced irreversible cell death 
by autophagy at doses above 15uM (90% inhibition at 25uM) in T98G cells and apoptosis in 
U937 Lymphoma cells. In contrast, DHEA, 17β-AED and 17β-AET did not produce cell death. 
17α-AED was then tested on GBM6, T98G, U87MG, LN-18, LM-Z308 Glioblastoma cells[158]. 
All cell lines could be induced to enter irreversible cell death by autophagy and at IC50 
concentrations between 8 and 25uM [158]. Additionally, it was discovered that 17α-AED 
 reduced AKT/mTOR signaling and induced autophagy through the induction of ATG5 and 
beclin-1 in these cell lines. Together, these observations suggested a mechanism that could 
induce different irreversible programmed death pathways in different cell types. 
 A hallmark of steroid hormones is that slight changes in hormone structure can lead to 
significant differences in biological functionality [159]. Due to this characteristic of steroid 
hormones, 6 androstene hormones with the hydroxyl groups at different positions were 
synthesized and tested to determine cytoxic effects on T98G Glioblastoma and U937 Lymphoma 
cells[160]. It was discovered that the position and orientation of the hydroxyl group at the 17 
position in relation to the cycloperhydrophenanthrene steroid ring and not the hydroxyl located at 
the 3 position was responsible for either autophagy or the apoptotic effect on Glioblastoma and 
Lymphoma cells respectively [160].  These observations suggest that the hydroxyl at the 17 
position impart 17α-AED with the ability to direct different programmed cell death pathways in 
different cell types and that these effects are through estrogen/androgen independent means. 
Because 17α-AED and 17β-AED, other than the orientation of the hydroxyl group at the 17 
position, are chemically identical, it is possible that 17α-AED could fit in the estrogen and 
androgen ligand binding pocket.  Despite the anti-proliferative activity, it is currently unknown 
whether 17α-AED interacts with the androgen and estrogen receptors.  
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 Pursuant to these observations, the mechanism of action of 17α-AED was investigated 
[161]. LN-18, LN-229, U87MG, LN-Z308, U251MG Glioblastoma cells were treated with 17α-
AED and members of the unfolded protein response were investigated since prior results 
implicated ATG5 and beclin-1 suggesting that a class III PI3K/p150 lipase signaling complex 
was involved [161]. Experiments were performed utilizing these multiple cell lines and T98G 
Glioblastoma cells transfected with either a double negative mutant PERK or an empty vector 
 control [159]. The results demonstrated that 17α-AED activated the double stranded RNA-
activated protein kinase (PKR)-like endoplasmic reticulum kinase (PERK) and not interferon-
inducible double stranded RNA dependent activator kinase (PKR), the eukaryotic translation 
initiation factor 2 alpha kinase 4 (GCN2) or the eukaryotic translation initiation factor 2-alpha 
kinase 1 (HRI) [161]. It was then further shown that phosphorylation of eLF2α occurred 
downstream of PERK activation which is consistent with translation attenuation [161]. 
Additionally, it was shown that the X-box binding protein 1 (XBP-1) was not cleaved while 
CCAAT/enhancer binding protein homologous protein (CHOP), glucose regulated protein of 78 
kDa (GP78) were elevated which further suggest a specific mechanism of action [161]. Together, 
these observations demonstrate that 17α-AED possesses mechanisms of action that are 
independent of estrogen and androgen receptors. 
 The unfolded protein response (UPR) typically involve the three endoplasmic reticulum 
transmembrane receptors: activating transcription factor 6 (ATF6), inositol requiring kinase 
(IRE1) and double stranded RNA-activated protein kinase (PKR)-like endoplasmic reticulum 
kinase (PERK) [162]. The UPR performs three functions; adaptation, alarm, and apoptosis [162]. 
Adaptation is associated with a translational block and expression of chaperones to aid in 
refolding [162]. If this is unsuccessful then the alarm phase is initiated which is associated 
initiation of signal transduction events that lead to removal of the translational block, 
downregulation of survival proteins (B-cell CLL/lymphoma 2 (BCL2)) and after the alarm phase 
ER stress can activate programmed cell death [162].  
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 While the activation of PERK by 17α-AED could be associated with a UPR, there are a 
few observations that are different from an ER unfolded protein response. First, the UPR is 
associated with IRE1 and ATF6 activation [162]. There was no activation of XBP-1 or activation 
 of either the IRE1 or ATF6 by 17α-AED [161]. The translational block was not released during 
autophagy induced in the Glioblastoma cells by the 17α-AED thus the translational block 
accompanied the induction of autophagy. Last, there was an expression of Grp78 which is 
consistent with the adaptation stage of the UPR. These results are consistent with a direct 
activation of PERK along with a sustained translational block leading to irreversible 
programmed cell death. The upregulation of CHOP and the signal transduction modulation 
implied by AKT/mTOR [158] suggests that there are specific transcriptional events that are 
associated with the activation of PERK by 17α-AED, however, further knowledge of these 
events are currently unknown. 
  
Overview 
The observations presented in this brief introduction of DHEA, 17β-AED, 17β-AET and 17α-
AED were intended to demonstrate the observations central to the idea that the androstene 
hormones exhibit a specific biological functionality that is dependent on their structure and 
conformation. The androstene hormones have been associated with the medically critical, cell-
specific responses of repair and survival or death. The wide range of beneficial effects 
demonstrated by the androstene hormones are associated with receptors and cytokines that are 
transcriptionally regulated by master transcription regulators that include NFkB, cFOS) and 
members of the nuclear receptor superfamily (AR, ERα, ERβ, GR). 
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  This dissertation was based on three hypotheses. In Chapter 1, the operating hypothesis 
is: Androstene Hormones, based on their putative ability to interact with the androgen and 
estrogen receptors and yet promote differential anti-glucocorticoid activity, will demonstrate 
differential activation of the human ERα, ERβ, AR and GR, at the level of the receptor and will 
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demonstrate decreased androgenicity or estrogenicity compared to 17β-estradiol and 
testosterone. In Chapter 2, because 17α-AED but not 17β-AED induces irreversible autophagy in 
Glioblastoma cells and that induction is associated with the chemical structure and conformation 
(specifically the hydroxyl group at the 17 position) of 17β-AED and 17α-AED then the operating 
hypothesis is: 17β-AED and 17α-AED will be associated with unique transcriptional regulation 
in Glioblastoma cells. Finally, in chapter 3, because 17β-AED regulates host resistance through 
skin associated immunity and possesses the ability to regulate transcription we tested the 
hypothesis that transcriptional regulators modulated by 17β-AED would influence genes which 
are significantly active in the pressure ulcer wound edges in comparison to the normal skin. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
CHAPTER 2: Structural Stereochemistry of Androstene Hormones Determines Interactions with 
Human Androgen, Estrogen, and Glucocorticoid Receptors 
 
 
Introduction 
 DHEA, an androstene hormone, has been shown to possess a wide range of beneficial 
biological effects mainly attributed to immune system modulation [163]. DHEA, is metabolized 
into more active metabolites i.e., 17β-AED, 17β-AET as well as testosterone and estradiol 
[163][164]. 17β-AED and 17β-AET have been reported to prevent the morbidity and mortality of 
otherwise lethal infections [89][165] potentiate lymphocyte activation and counteract the 
immune suppressive action of hydrocortisone [166][167] thus leading to beneficial effects in 
diverse human diseases including resistance to infection, neuroprotection, wound healing, 
diabetes, hepatic injury, cardiovascular disease and cancer [168-170].  
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 17α-AED mediates autophagy of glial and breast cancers and apoptosis of myeloid tumor 
cells [154][160][171]. 17β-AED and 17α-AED naturally exist in epimeric forms based on 
whether the hydroxyl group is above (β) or below (α) the Δ5 cycloperhydrophenanthrene ring. 
Addition of a hydroxyl group at the C7 position to 17β-AED results in the formation of Δ5-
androstene-3β, 7β, 17β-triol (17β-AET). The biological activities of 17α-AED, 17β-AED and 
17β-AET have exhibited a structure-activity relationship that depends on the orientation and 
location of the hydroxyl groups [172]. Androstene hormones (AH) have been shown to 
promulgate their biological effects in many different animal models including mice, rats, 
 25 
monkeys and some specific human tissues. Reports have associated the mechanism of action of 
androstene hormone metabolites with androgen, estrogen and glucocorticoid receptor activity 
[112][118][145]. Adrenal hormones have been shown to activate both androgen and estrogen 
constructs. In this regard, it has been documented that 17β-AED can activate the AR receptor in 
prostate tissue in the presence of commonly used anti-androgens [173]. Inhibitors of both the 
androgen receptor and the estrogen receptors demonstrated that AR and ERβ receptors combine 
to affect gene transcription [174] Additionally, 17β-AED was recently shown to be a part of an 
anti-inflammatory mechanism that utilizes the ERβ [148]. 17β-AED and 17β-AET have been 
documented in vitro and in vivo to oppose the action of hydrocortisone indicating that there may 
be crosstalk with the GR receptor [78][91][92].  
 DHEA has been shown to possess weak androgenicity and estrogenicity [175]. Because 17α-
AED, 17β-AED and 17β-AET are more potent metabolites of DHEA that exhibit strong 
biological activity that could be attributed to androgenic, estrogenic or anti-glucocorticoid 
activity in vivo and in vitro it was advantageous to identify whether or not this is directly 
mediated by the human ER, AR and GR receptors at the cellular level. Additionally, 
androstenediol has been modeled as a chemical with a 3β-hydroxy and a saturated A ring which 
can act as an estrogen [176]. Consequently, we compared DHEA, 17α-AED, 17β-AED and 17β-
AET in the Indigo Biosciences nuclear receptor assay system for their ability to activate the 
human AR, ER and GR receptors and determine the relative androgenicity and estrogenicity of 
these androstene hormone derivatives. 
 
 Methods 
Nuclear Receptor Transactivation Assays  
  Nuclear receptor transactivation assays were obtained from Indigo Biosciences(State 
College, PA, USA) and were utilized to assess activation of human AR, ERβ and ERα. receptors. 
Briefly, stocks of the compounds tested were prepared and diluted in medium provided by the 
manufacturer. Cell medium was tested for hormone activity by mass spectrometry. Frozen 
reporter cells provided in the assay kit were thawed and compound dilutions were added 
immediately. Cells were incubated for 24 hours and the activation response was measured on a 
luminometer (Perkin-Elmer, MA,,USA). The cells consisted of non-human mammalian cells 
engineered by Indigo Biosciences to provide constitutive high-level expression of full length, 
unmodified human androgen Receptor (NR3C4), human estrogen receptor 1 (NR3A1), human 
estrogen receptor 2 (NR3A2) and of full length, human glucocorticoid Receptor (NR3C1).  
 The non-human mammalian reporter cells included a luciferase reporter gene functionally 
linked to a human nuclear receptor-responsive promoter. The cells are engineered so that only 
interactions with the human receptor will induce luciferase expression in the treated reporter 
cells to quantitate nuclear receptor activation. Positive control ligand performance was measured 
by the manufacturer and provided in the technical manuals thus allowing accurate comparison 
for assay performance. Additionally the control ligands of the receptors (testosterone, 17β-
estradiol, dexamethasone) were tested on the same test plates (n=3 to allow statistical analysis) 
with the androstene hormones and controls.  
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 Preparation of Stock Hormone Solutions 
 Stock solutions of 17β-AED, 17α-AED, Testosterone (Sigma-Aldrich, St. Louis, MO, USA) 
were prepared by dissolving the compounds into 100% ethanol to a final 50 mM stock solution 
concentration; 17β-AET was also a stock solution of 50 mM but was dissolved into 1:1 
DMSO/Ethanol because of solubility issues. Cyproterone Acetate (Sigma-Aldrich) was diluted 
with 100 % ethanol and used at a 10 uM concentration. All stock solutions were diluted to final 
concentrations using the dilution fluid provided in each kit. All tests were performed with 
negative controls on the same plate and contained media alone and media containing the same 
amount of ethanol utilized in the stock solutions. All assay control results were in accordance 
with the stated technical performance specifications.   
 
Mass Spectrometry 
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LC-MS/MS analysis of the steroid hormones were carried out using a Shimadzu Nexera UPLC 
device coupled (Shimadzu Corp, Kyoto, Japan) to ABSciex (Foster City, CA) 5500 Hybrid 
Triple Quadrapole Linear Ion Trap Mass Spectrometer operating in multiple reaction monitoring 
mode. Nitrogen produced by a high-purity nitrogen generator (PEAK Scientific Instruments Ltd, 
Chicago, Ill) was used as curtain, nebulizer and collision gases. Unit mass resolution was set in 
both mass-resolving quadrupole Q1 and Q3 Ionization of the analytes were carried out using an 
APCI source. Multiple MRM transitions were selected for each analyte to eliminate ambiguity in 
analyte identification. For all steroids other than AED, 25 microliters of the media was directly 
injected onto a 2.1 x 50mm 2.6 μm C18 Reverse Phase column (Phenomenex) and was separated 
via a linear gradient of water:methanol 98:2 (Solvent A) to methanol:water 70:30 (Solvent B). 
Both solvents contained 5mM ammonium formate with 1% formic acid.  Separation of 17α-AED 
 and 17β-AED was carried out using 2.1 x 150 mm 2.6μm C18 Reverse Phase column 
(Phenomenex) and was separated using same Solvent A as above and 98:2 methanol: water with 
5mM ammonium formate and 1% formic acid as Solvent B. Steroid hormones were detected 
using precursor-product MRM pairs are as follows; DHEA (271-213, 271-197), Androstenetriol 
(307-158, 307-254), Androstenediol (291-95, 291-159, 291-255), Testosterone (289-97, 289-
109), Androstenedione (287-97, 287-109), 17β-estradiol (273-107, 273-135, 273-77). Where 
there were multiple transitions, the dominant peak was used in the analysis. All analytes 
demonstrated a minimal limit of detection of at least 0.6 nM.  
 
Cellular Uptake of Androstene Hormones and Normalization of Transactivation Assay Results 
 It was relevant to determine the relative uptake of each androstene hormone in the Indigo 
Assay System. Cells and cell medium utilized in the assays were provided by the manufacturer 
(Indigo Biosciences). The following components were found to be below the limit of detection in 
the cells and cell medium: DHEA, 17β-estradiol, androstenedione, testosterone, 17α-AED, 17β-
AED and 17β-AET.  LCMS data was utilized as a ratio between the background subtracted 
signal (area under the curve of the LCMS trace) at time zero and 24 hours for each analyte 
investigated. The ratios were then utilized to create normalization factors for the cellular uptake 
of 17α-AED, 17β-AED and 17β-AET as compared to DHEA. The normalization factors were: 
DHEA: 1, 17α-AED: 1.71, 17β-AED: 1.85, 17β-AET: 2.40, respectively. Background activity 
due to cells, media and vehicle were subtracted before the data were normalized.  
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 Metabolism of Androstene Hormones 
 The cell medium was analyzed before and after incubation with assay cells. Mass 
Spectroscopy was utilized to detect androstenedione, 17β-AED, 17α-AED and 17β-AET, 
testosterone and 17β-estradiol that were expressed in the medium. Approximately 9% of DHEA 
was metabolized to 17β-AED after a 24 hour incubation with assay cells. No other DHEA 
metabolites were detected. Mass spectroscopy did not detect any metabolites of the other 
androstene hormones in the media after a 24 hr incubation period. The Mass Spectrometry data 
show that DHEA was minimally metabolized to 17β-AED in this cell construct, but not to 
testosterone or 17β-estradiol (Methods 2.3.2). 17β-AED, 17β-AET and 17α-AED were not 
metabolized. 
 
Statistical Analysis 
All statistical analyses were performed using SigmaPlot version 12(SSI, San Jose, CA, USA).  
Hormone EC50 level and the estrogen receptor alpha activation statistical analyses were 
performed with a student's t test while all other hormone activation statistical comparisons were 
performed with a one-way ANOVA.  p value levels < 0.05 were considered significant. Statistics 
on test groups were done before normalization to cellular uptake and were performed between 
test groups and controls.  
 
Results and Discussion 
Androstene hormone structures  
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 The hormones that were used in this study are listed in Figure 1. The structures demonstrate 
the similarities and unique characteristics of each androstene hormone. The main differences are 
 the orientation of the hydroxyl group at position C17 for 17α-AED and 17β-AED, the orientation 
and position of the hydroxyl group at position C7 for 17β-AET, and the ketone group at position 
17 for DHEA. 17α-AED and 17β-AED are chemically identical except for the placement of the  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  The structures of the Androstene Hormones  
30 
   The androstene hormones are shown with the Δ5 cycloperhydrophenanthrene  ring. All 
steroids have a C3 hydroxyl group in the (β) beta position. The C7 hydroxyl group of 
Androstenetriol is in the β-position. The C17 hydroxyl of Androstenediol epimers are in either 
the (α) alpha or (β) beta position. 
 hydroxyl group in relation to (above or below) the Δ5 cycloperhydrophenanthrene ring. All 
adrenal hormones in this study, with the exception of DHEA, possess hydroxyl groups in the C3 
and C17 position with 17α-AED having the C17 hydroxyl group in the (α) position. This 
position at C17 results in remarkable biological actions [154][160] while the hydroxyl group at 
C3 was shown not to influence the biological activity [177].  
 
Androstene Hormone Activation of the Human AR receptor 
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 The data demonstrate that both the orientation of the hydroxyl at position C17 and the 
addition of the hydroxyl at position C7 affected the ability of 17β-AED, 17β-AET and 17α-AED 
to activate the human AR construct (Figure 2). The AR receptor construct contains a luciferase 
reporter gene that is functionally linked to an AR responsive promoter. The luciferase reading is 
utilized as a surrogate measure for AR binding. The EC50 was calculated for testosterone as the 
50% activation point. EC50 values for the androstene hormones and testosterone were calculated 
(Table 1.) and compared utilizing the ratio of the androstene hormone EC50 to testosterone EC50 
(Relative Androgenicity). All of the androstene hormones tested showed a significant (p<0.001) 
reduced androgenicity when compared to testosterone (Table 1). 17β-AED had only 1/5th the 
ability of testosterone to activate the androgen receptor. Changing the orientation of the C17 
hydroxyl group on 17α-AED resulted in a further reduction to 1/60th the activity as compared to 
testosterone. Addition of the hydroxyl group to the C7 position further reduced the ability to 
activate the human AR construct to 1/1326th as that of testosterone. The androstene hormone 
activation of the human AR was rank ordered based on strength of activation. The rank order 
was: 17β-AED>>17α-AED>>>17β-AET (Figure 1). DHEA binding to the AR receptor was 
excluded from these experiments since its androgenicity has been reported previously [175].  
  
Figure 2.   Androstene Hormone Activation of the Human Androgen Receptor  
 
 Reporter cells were treated with 17α-AED or 17β-AED or 17β-AET (n=3) at each 
concentration, incubated for 24 hours and then assayed for luciferase activity. Androstene 
hormone activity was normalized to cellular uptake (Methods). Error Bars, ± 1SD. Statistical 
significance, p <0.001 versus androstene hormone metabolites in the same concentration group 
(¤), p<0.001 versus androstene hormone metabolites in the same concentration group (*).  
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 Table 1.  Relative Androgenicity of Androstene Hormones  
 
 
Hormone                                EC50(nM)                   Androgenicity                     p Value    
 
Testosterone 0.35       1          1 
Δ5-androstene-3β, 17β-diol  1.8                           1/5  <0.001 
Δ5-androstene-3β, 17α-diol  21 1/60    <0.001 
Δ5-androstene-3β, 7β, 17β-triol             464    1/1326  <0.001 
 
The EC50 was calculated as the 50% activation point. The androgenicity is the testosterone EC50 divided by the androstene hormone EC50. This 
data does not normalize the cellular uptake of androstene hormones. 
 
 
Androstene Hormone Activation of the human ERβ and ERα receptors  
 The data demonstrate that both the orientation of the hydroxyl at position C17 and the 
addition of the hydroxyl at position C7 affected the ability of DHEA, 17β-AED, 17β-AET and 
17α-AED to activate the human ERβ construct (Figure 3). The ER receptor construct contains a 
luciferase reporter gene that is functionally linked to an ER responsive promoter. The luciferase 
reading is utilized as a surrogate measure for ER binding. The EC50 was calculated for 17β-
estradiol as the 50% activation point. EC50 values for the androstene hormones and 17β-estradiol 
were calculated (Table 2) and compared utilizing the ratio of the androstene hormone EC50 to 
17β-estradiol EC50 (Relative Estrogenicity). All of the tested androstene hormones demonstrated 
a significantly (p<0.001) decreased estrogenicity compared to 17β-estradiol (Table 2.). 17β-AED 
had only 1/282 the ability of 17β-estradiol to activate the ERβ. The orientation change of the 
hydroxyl group at position C17 of 17β-AED to the(α) position resulted in 17α-AED possessing 
1/7609th the ability of 17β-estradiol to activate the ERβ receptor as 17β-estradiol. This 
represents a drastic decrease in estrogenicity from the 17β-AED epimer. The presence of the 
hydroxyl group at C7 of 17β-AET resulted in 1/587th the ability to activate the ERβ. DHEA, 
with a ketone group in the C17 position, possessed 1/3543rd the ability to activate the ERβ. 
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  The rank order of androstene hormone activation on the human ERβ receptor can be 
displayed as follows: 17β-AED >17β-AET >DHEA>17α-AED (Figure 3).  
 
 
 
 
Figure 3. Androstene Hormone Activation of the Human Estrogen Receptor Beta  
 Reporter cells were treated with 17α-AED or 17β-AED or 17β-AET or DHEA (n=3) at each 
concentration, incubated for 24 hours and then assayed for luciferase activity (n=3), incubated. 
Androstene hormone activity was normalized to cellular uptake. Error Bars, ± 1SD. Statistical 
significance, p<0.001(¤) versus androstene hormone metabolites in the same concentration 
group, p< 0.001(*) versus lower reacting androstene hormones in the same concentration group 
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 These androstene hormones also specifically activated the human ERβ receptor and 
demonstrated the crucial effect of the (β) C17 hydroxyl group. 17β-AED and 17α-AED activated 
the ERβ receptor 2 and 3 orders of magnitude lower respectively than 17β-estradiol (Table 2). 
The 17β-AED demonstrated an estrogenicity of 1/1176 when assayed on the human ERα. 
Activation of the ERα receptor by 17β-AED did not become apparent until the concentration 
Figure 4.  17β-AED Activation of the Human Estrogen Receptor Alpha 
 Reporter cells were treated with 17β-AED (n=3), incubated for 24 hours, and  then assayed 
for luciferase activity. 17β-AED activity was normalized to cellular uptake, Error Bars, ± 1SD.  
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reached 25 nM (Figure 4) which was 3 orders of magnitude lower than 17β-estradiol further 
demonstrating the weak estrogenicity displayed by these hormones at the level of the ER 
receptors. Finally, it should be noted that the androstene hormones only weakly activated the AR 
receptor and were even weaker activators of the human ER receptors. 
  
Table 2: Relative Estrogenicity of Androstene Hormones  
 
 
Hormone                                            EC50(nM)               Estrogenicity                          p Value 
 
17β-estradiol               0.046                        1                                    1        
Δ5-androstene-3β, 17β-diol               13                         1/282                         <0.001 
Δ5-androstene-3β, 7β, 17β-triol            27                         1/587                         <0.001 
DHEA                   163                       1/3543                       <0.001 
Δ5-androstene-3β, 17α-diol                  350                       1/7609                       <0.001 
 
The EC50 was calculated as the 50% activation point  The estrogenicity is the 17β-estradiol EC50 divided by the androstene hormone EC50.  This 
data does not normalize the cellular uptake of androstene hormones.  
 
 
Androstene Hormones Activation of the Human Glucocorticoid (GR) Receptor  
 17β-AED, and especially 17β-AET are known to produce significantly affect glucocorticoid 
activity in vivo [92][78][91]. Therefore, the human GR construct response to 17β-AED, 17β-
AET, DHEA and 17α-AED alone and in combination with dexamethasone was evaluated. The 
results showed dexamethasone alone activated the human GR receptor while17β-AED, 17β-
AET, DHEA, and 17α-AED alone were negative at all concentrations tested (Figure 5).  
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Figure 5.  Dexamethasone or Androstene Hormone Activation of the Human     
Glucocorticoid Receptor 
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   Reporter cells were treated with dexamethasone or androstene hormones alone (n=3), 
incubated for 24 hours, and then assayed for luciferase activity. Androstene Hormones are: 
DHEA, 17β-AED, 17α-AED and 17β- AET.  Error Bars, ± 1SD.   
  The human GR receptor was then tested for activity with androstene hormones in the 
presence of dexamethasone. Unexpectedly, at supra-pharmacological levels of dexamethasone 
there was a considerable activation of the human GR receptor by 1 µM of each of the androstene 
hormones, which was greater than with dexamethasone alone with a higher activity when 
dexamethasone concentration was increased from 333pM to 1000 pM (Figure 6).  
 The rank order of activation of the dexamethasone-bound human GR receptor in the presence 
of the androstene hormones is: 17β-AET>17β-AED>17α-AED>DHEA. These data demonstrate 
that the C7 hydroxyl present in 17β-AET produced the strongest activation of the 
dexamethasone-bound human GR. The (β) C17 hydroxyl of 17β-AED produced a stronger 
activation than did the (α) C17 hydroxyl of 17α-AED. Thus, while 17β-AED and 17α-AED 
produced unique activation of the dexamethasone-bound human GR, the effect of the C17 
hydroxyl group conformation was less apparent. DHEA, which has the keto group in the C17 
position, possessed the least ability to activate the dexamethasone-bound human GR.  
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Figure 6.  Androstene Hormones and Dexamethasone Activation of the Human GR 
Receptor  
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 Reporter cells were treated with dexamethasone alone or a combination of dexamethasone 
and androstene hormone, incubated for 24 hours, and then assayed for luciferase activity.(n=3). 
Androstene hormone activity was normalized to cellular uptake. Error Bars, ± 1SD. Statistical 
significance, p is at least <0.05 from other androstene hormone metabolites within the 
dexamethasone concentration treatment group (¤), p is <0.05 versus control (*), p is <0.05 from 
333pM dexamethasone treatment group (●). 
  We next tested these effects with the dexamethasone inhibitor, cyproterone acetate to see if 
we could reduce or eliminate the dexamethasone and androstene hormone activation of the 
human GR receptor. Cyproterone acetate was selected as the inhibitor because of its unique 
glucocorticoid receptor inhibiting properties [178]. Cyproterone effectively inhibited the 
activation of the human GR receptor by dexamethasone (Figure 7). Cyproterone acetate at a 
concentration of 10uM was tested in the presence of the androstene hormones alone (1.0 uM) 
and there was no activation detected (data not shown). Androstene hormones, however in the 
presence of cyproterone and dexamethasone exhibited different levels of activation that were 
significantly increased above the dexamethasone/cyproterone alone controls (Figure 7). These 
results are of particular clinical significance because it demonstrates that high dose 
dexamethasone alters the human GR receptor to interact with other biologically active hormones 
at the receptor level. Importantly, dexamethasone, is known to cause adverse effects in humans 
[179]. 
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Figure 7.  Androstene Hormone and Dexamethasone Activation of the Human GR         
Receptor in the presence of Cyproterone Acetate 
 
 Reporter cells were treated with dexamethasone and cyproterone acetate alone       
or androstene hormones with dexamethasone and cyproterone acetate (n=3), incubated for 24 
hours, and then assayed for luciferase activity. Androstene  hormone activity was normalized to 
cellular uptake. Error Bars ± 1SD, Statistical significance, p is <0.05 from other androstene 
hormone metabolites within the dexamethasone treatment group (¤), p<0.05 from  
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controls (*). 
  The rank order of activation of the dexamethasone/cyproterone acetate-bound human GR in 
the presence of these androstene hormones is: 17β-AET>17β-AED>17α-AED>DHEA. This 
rank order of activation on the inhibited human GR was the same as that of the uninhibited 
human GR indicating that the interaction of the androstene hormones and the 
dexamethasone/cyproterone-bound human GR was not disrupted. Because cyproterone acetate is 
a passive inhibitor of the human GR receptor and opposes dexamethasone through an 
overlapping steroid scaffold mechanism, this suggests that the androstene hormone activation is 
mediated by an interaction that occurs outside the dexamethasone/cyproterone acetate-bound 
complex [178]. Additionally, the presence of dexamethasone-bound human GR is required to 
observe activation by the androstene hormones while cyproterone acetate alone does not mediate 
this effect. Together these data suggest an indirect activation of the ligand-bound human GR 
receptor by 17β-AET, 17β-AED, 17α-AED and DHEA.  
 
Summary 
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 These results indicate that the position of the hydroxyl group at C17 and/or the addition of 
the hydroxyl group at position C7 significantly affected the ability of 17β-AET, 17β-AED, 17α-
AED and DHEA to interact with the human estrogen, androgen and ligand-bound GR receptors. 
17β-AET, 17β-AED, 17α-AED and DHEA were shown to interact either directly or indirectly 
with the human (AR, ER) and GR respectively. Importantly, 17β-AET, 17β-AED, 17α-AED and 
DHEA were shown to possess weak androgenicity and even weaker estrogenicity at the receptor 
level. Clinically, this is beneficial because the biological effects can be realized without 
unwanted androgenic or estrogenic effects.  
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 In stark contrast to the minimal receptor activation of AR, ER and GR, these same 
androstene hormones produce striking biological effects in vitro and in vivo which have been 
attributed to activity with the AR, ER or GR receptors. Clearly, these effects may not be 
mediated by the direct androstene hormone interaction with the human AR, ERα, ERβ and GR 
receptors. Indeed, the biological mechanism, may not require AR or ER receptors to achieve 
significant effects [155][180]. Furthermore, the interaction with dexamethasone is indirect, 
occurs at high doses and is not abolished by cyproterone acetate. Taken together, the data shows 
that interactions of 17β-AET, 17β-AED, 17α-AED and DHEA with the human AR, ERα, ERβ 
and GR receptors are directed by the structure-activity of these androstene hormones with 
minimal androgenic, estrogenic or glucocorticoid effects and accentuates the need to further 
uncover the implied yet unidentified main mechanism (s) of action of these important adrenal 
hormones. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 3: Androstene Hormone Epimers Regulate ER Stress and Core Regulatory Genes in 
Human T98G Glioma Cells.
 
 
 
 
Introduction 
 High grade gliomas represent approximately 50% of the primary central nervous 
system(CNS) tumors with 15,000 cases diagnosed in the United States each year [181].Grade IV 
glioblastomas (Glioblastoma Multiforme) are World Health Organization(WHO) classified as 
astrocytic neoplasms derived from the glial lineage that have progressed from Grade III(high 
proliferation) to Grade IV(necrotic tissue and/or angiogenic activity)[182][183][184][185].  The 
mean life expectancy of patients with Glioblastoma Multiforme is only 1 year from the time of 
initial diagnosis and only several months after progression [186]. The traditional therapy for 
these aggressive tumors is surgical resection followed by external beam radiation and/or 
chemotherapy, however, these treatments are considered palliative with only a very low survival 
rate. Temozolomide, an oral alkylating agent that enters the CNS, is the most commonly used 
chemotherapy treatment alone or in combination with compounds known to induce cell death 
[187][188]. Temozolomide, an oral alkylating agent, however, only improves the lifespan of 
malignant glioma patients by 2-3 months [187]. A major obstacle to complete tumor resection is 
the high invasiveness of the tumors [8].  
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 Human derived T98G cells are a well characterized in vitro model of glioblastoma [189]. 
These cells were obtained from a 61 year old male and became spontaneously polyploid through 
culture passage [190]. T98G glioblastoma cells have been utilized as a model system for 
 targeting Glioblastoma Multiforme pathways [191]. T98G cells contain functional 
PDGF(Platelet Derived Growth Factor) receptors that can induce a malignant phenotype with 
sufficient stimulation [192][193]. T98G cells contain multiple mutations that have contributed to 
their tumorigenic properties. These mutations include a homozygous mutation for p53, 
CDKN2A deletion and PTEN mutation [193][194]. Transformation of T98G cells by PDGF 
combined with the loss of tumor suppressor activity is associated with three signaling pathways 
that are crucial in Glioblastoma [193].  
 Δ5-androstene-3β, 17α-diol (17α-AED) has been shown to produce definitive type II 
programmed cell death in T98G cells (Figure 8) [157]. The mechanism whereby 17α-AED 
induces oncophagy in T98G cells has previously been identified and described [195][196]. Δ5-
androstene-3β, 17β-diol (17β-AED) is the epimer of 17α-AED. These naturally produced adrenal 
hormones are chemically identical and differ only in the stereoisomeric position of the hydroxyl 
group located at carbon 17 of the steroid ring structure. 17β-AED, in opposition to 17α-AED, 
does not produce cell death in T98G Glioblastoma cells (Figure 8) [196]. 17β-AED, in fact, 
promotes significant biological effects including the enhancement of the immune system 
[81][197] even in the presence of glucocorticoids [112][109] and provides protection against 
lethal radiation [198]. The relationship of chemical structure to biological 
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Figure 8: Contrasting Effects on Cell Morphology of T98Glioma cells treated with 17α-
AED or 17β-AED. Prior confirmation of autophagy in cells treated with 9.5 uM of 17α-AED 
was performed with electron microscopy [16]. Cells were stained with hematoxylin and eosin 
and visualized with light microscopy at 100x. Left panel demonstrates autophagy induced by 
17α-AED while the right panel demonstrates the lack of apoptosis or autophagy in 17β-AED 
treated cells. 
 
 
function is shown in Figure 9 and Table 3 lists the opposing biological functions of 17β-AED 
and 17α-AED.  
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Figure 9: Structure-function relationship of the 17 hydroxyl position of the chemically 
identical androstenediol epimers, 17α-AED and 17β-AED results in opposing biological 
functions. The 17α-AED results in oncophagy (target cell specific cell death by apoptosis or 
autophagy) while the 17β-AED result in Immune Upregulation (adapted from Loria and Graf 
(2012). 
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 Many large-scale investigations into complex human disease have been performed and 
genome wide analysis of RNA expression is a common way to investigate complex human 
disease. It has been stated that the major challenge of these investigations is to gain relevant 
biological insight into these diseases [199]. 17α-AED and 17β-AED are chemically identical, 
produce either cell survival or irreversible death, and the biological actions of 17α-AED have 
 been partially identified. Clearly these epimers are ideal for monitoring the “mirror” effects 
observed in human Glioblastoma cells.  Thus, we utilized these hormones, signal targeting 
microarray genes and Ingenuity IPA® networking software to demonstrate that these 
stereoisomers regulate core transcriptional regulators and influence critical signal transduction 
pathways that are critical for the death or survival of Glioblastoma.  
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 TABLE 3: Biological Function of 17α-AED and 17β-AED    
 
Hormone 
 
Model  
Type 
 
Cell        
Type(s) 
 
Biological                Function(s) 
 
References 
          
17α-AED In vitro ZR-75-1 MCF-7 1) Inhibition of DNA Synthesis (Huynh et al., 2000) 
      2) Androgen and Estrogen independent 
inhibition of tumor cell proliferation 
  
         
      3) Combined treatment of 17α-AED and 
17β-AED potentiated the effect of 17α-AED 
  
          
  In vitro T98G U937 1) 17α-AED induces autophagy in the 
glioblastoma cell line(T98G) 
(Loria and Graf, 2012) 
          
      2) 17α-AED induces apoptosis in the 
myeloid cell line(U937) 
  
          
      3) Type of cell death induced by17α-AED is 
determined by the target tissue  
  
          
  In vitro T98G     
U87MG 
U251MG       
LN-18           
\N-229         
LN-Z308 
1) Autophagy induced specifically through 
PERK/CHOP/ GRP78/elF2α /BECLIN/LC3  
signaling and not through IRE1 or ATF6 
(Loria et al., 2012)(Jia et al., 2010) 
          
      2) Inhibition of elF2α in T98G cells by 
introduction of elF2αS51A dominant 
negative inhibited the induction of 
autophagy by 17α-AED 
  
          
      3) ER stress is linked to 17α-AED induced 
autophagy by PERK/elF2α signaling 
  
          
  In Vitro MCF-7    MDA-
231 T47D     
TTU-1 
1) Enhanced radiation cytotoxicity and 
autophagy induction in human breast cells 
(Loria et al., 2012) 
          
      2) Estrogen independent inhibition of tumor 
cell proliferation 
  
      3) Autophagy induced through 
PERK/CHOP/elF2α signling 
  
          
  In vitro T98G 1) The position of the hydroxyl located at 
carbon-17 of the chemically identical 
stereoisomers of androstenediol dictates the 
biological effect. 
(Graf et al., 2009) 
      2) The 3-hydroxyl position was found to not 
influence biological effects. 
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 TABLE 3: Biological Function of 17α-AED and 17β-AED (Continued) 
     
     
17β-AED In vitro HL-60 P388D1 1) Does not inhibit DNA synthesis at 
concentrations that produced 
irreversible cell death with 17α-AED 
(Huynh, P, Loria, R.M, 1997)  
      2) High doses did decrease DNA 
synthesis 
 
         
  In vivo ZR-75-1 MCF-1 1) 17β-AED shown to increase the 
proliferation of ZR75-1 and MCF-7 
cells 
(Poulin, R., Labrie, F., 
1986) (Hackenberg, R. et al., 1993)
         
  In vivo CD-1 Mice 1) Protection from lethal infections of 
Pseudomonas aeruginosa and 
Enterococcus faecalis 
(Ben-Nathan et al, 1999)  
         
  In vivo Male Sprague 
Dawley Rats 
1) KLF6, BCL2, p53 upregulated by 
17β-AED leading to downregulation of 
iNOS and 
(Kiang et al., 2007)  
         
  In vivo CD-1 Mice 1) In wound healing: countered the 
suppressive effect of restraint on 
MCP-1 and IL-1 expression in mice 
(Head et al., 2006) 
         
  Ex-vivo Murine 
Lymphocytes 
1) Minimally counteracts 
hydrocortisone suppression of IL-2/IL-
3 production and cell proliferation and 
does not cause splenocyte 
proliferation 
(Padgett and Loria, 1994)  
         
17α-AED/ 
17β-AED 
In vitro Assay Cells 1) 17α-AED and 17β-AED differentially 
and directly activate human estrogen 
alpha, estrogen beta, androgen and 
indirectly activate glucocorticoid 
constructs at the level of the receptor 
in a whole cell construct with markedly 
decreased androgenicity and 
estrogenicity  
[200]  
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 Methodology 
Cell culture 
 T98G Glioblastoma cells were culture in Dulbecco's modified Eagle's medium 
supplemented with 10% fetal bovine serum and nonessential amino acids as adherent monolayers 
at 37oC, passed biweekly with trypsin in the absence of antibiotics. All tissue culture reagents 
and supplements were obtained from Invitrogen (Carlsbad, CA). The human T98G line was 
acquired from the American Type Culture Collection (Manassas, VA) and maintained by the 
Neuro-Oncology Research Group at the Virginia Commonwealth Medical Center, Richmond, 
VA.  
 
Androstene Hormone Controls 
 17α-AED and 17β-AED are chemically identical and the control was running both 
hormones in parallel. The only difference between these hormones is the stereoisometric position 
of the hydroxyl located at the C17 position (Figure 9). Therefore, qPCR confirmation was not 
necessary as only those genes displaying opposite regulation were considered in the analysis. 
 
The Human Signal Transduction Pathway Finder Microarray 
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 OligoGEArray, catalogue number OHS-014, (SuperArray Bioscience Corporation, 
Frederick, MD) was utilized to identify genes regulated by 17α-AED and 17β-AED in T98G 
cells. After an overnight incubation, cell medium was replaced and the T98G Glioma cells 
(1x104/well) were cultured in a 6-well, tissue culture plate in the presence of 9.5 uM 17α-AED or 
17β-AED (provided by Dr. Loria). This concentration is the IC50 of 17α-AED treated T98G 
cells. Cells demonstrated morphology consistent with prior studies.  Control wells were treated 
 with vehicle (50% PEG 400/50% ethanol). After a 20 hour incubation, the medium was removed 
and RNA was extracted from cells utilizing an RNAeasy kit (Qiagen, Valencia, CA) and 
quantitated spectrophotometrically. 1 ug/ml RNA was utilized with 3 uL GEAprimer Mix and 6 
ul H2O in the annealing mixture for probe synthesis. This mixture was heated at 70oC for 3 min 
then cooled to 42oC and then incubated at 42oC for 2 min. Labeling mix was then prepared by 
mixing 4ul of 5X GEA labeling Buffer, 3ul of [a-32P] dCTP (10mCi/ml), 1ul RNase inhibitor, 
1ul Reverse transcriptase (50U/ml) and 1ul of RNase free H2O. The labeling mix was then added 
to the RNA and the labeling reaction was run for 25 min at 42oC. The reaction was stopped with 
2 ul of stop solution then denatured with 2ul of denaturing solution at 68oC for 20 min after 
which probe neutralization was performed with 20 ul of neutralization solution at 68oC for 10 
min. Labeled probes were mixed with hybridization buffer and added to a prehybridized 
membrane and incubated overnight at 60oC. The hybridized membrane was washed 2x with 
SSC, 1% SDS for 10min at 60oC then washed once with 0.1x SSC, 0.5% SDS for 10 min at 60oC 
igure 10). 
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Figure 10: Human signal Transduction Pathway Finder Microarray 
 Human T98G Glioma cells were treated with vehicle or neuro-steroid for 20h. Total RNA 
was used to generate cRNA which was them used to probe the microarrays which contain DNA 
oligos from genes related to cell stress, cell toxicity, drug resistance and drug metabolism. Spots 
that are contained in the heavy circles represent housekeeping genes (β-actin, β2-microglobulin, 
ribosomal protein 27a, etc.) used to normalize the data. The light circle represents an internal 
control for orientation.  
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 IPA Network Generation and Analysis 
Network Generation 
An Ingenuity IPA® core analysis was performed where the identified target genes overlaid onto 
a global molecular network developed from information contained in the IPA database. The 
Ingenuity Knowledge Base Includes: Data Sources scanned included Ingenuity expert findings®, 
mi records, TaRbase, TargetScan Human, BIND, BIOGRID, Cognia, DIP, INTACT, 
Interactome studies, MINT, MIPS, ClinicalTrials.gov, GeneOntology, GVK Biosciences, Kyoto 
Encyclopedia of Genes, miRBase and the Obesity Gene Map.  
 
Network Score Statistics 
The network score is a statistical numerical value used to estimate how well the network 
eligible genes match the Ingenuity Knowledge Base genes. The score takes into account the total 
number of network eligible molecules, network size, and the total number of possible associated 
molecules in the Ingenuity Knowledge Base.  The Network Score is based on the hypergeometric 
distribution and is calculated with the right-tailed Fisher's Exact Test. For example, a network of 
35 molecules has a Fisher Exact Test result of 1x10-8. The network’s Score = -log (Fisher's Exact 
test result) = 8. This is interpreted as there is a 1 in a 100 million chance of obtaining the 35 
molecule network containing network eligible molecules randomly that could be in networks 
generated from the Ingenuity Knowledge Base.  
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 Results and Discussion 
The Human Signal Transduction Pathway Finder Microarray 
Microarray results were imaged on a phosphoimager. The acquired images were 
extracted and converted into raw signals using GEArray ScanAlyze software. The procedure is 
found at:(http://www.sabiosciences.com/manuals/GEArrayAnalyzerTutorial.ppt#278, 27, Chart).  
Probe sets were compared and normalized to β-actin controls (Figure 11).  
 
 
 
 
 
 
55 
 
  
Figure 11: Contrasting Effects on Gene Expression in T98Glioma cells treated with 17α-
AED or 17β-AED. A) Decreased gene expression in T98G cells treated with 17α-AED. Green 
marks below the vertical represent genes in T98G cells treated with 17α-AED that have a greater 
than 5-fold decrease in expression as compared to T98G cells treated with vehicle. Data 
normalized to β-actin gene expression. B) Same as in A, however T98G cells were treated with 
9.5 uM of 17β-AED. Numerous genes show a more than 5-fold increase in expression as 
indicated by red marks above the vertical.  
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 Network Analysis  
 All 26 target gene probesets were mapped to their corresponding gene in the IPA 
Knowledge Base through the GenBank ID number. The IPA core analysis yielded a total of five, 
35 molecule networks which were based on a score. The score takes into account the total 
number of network eligible genes, network size, and the total number of possible associated 
molecules in the Ingenuity Knowledge Base. The network scores for the network analysis are as 
follows network 1: (score: 16), network 2: (score: 12), network 3: (score: 12), network 4: (score: 
10), network 5: (score: 1). It should be noted that network 5 (1 in 10 chance of occurring 
randomly) is not statistically significant while the first 4 networks are extremely statistically 
significant. Network 1 has a 1 in 10 zillion chance of being random, networks 2 and 3 have a 1 in 
1 trillion chance of being random and network 4 has a 1 in 10 billion chance of being random.  
Target Genes 
         The term "Target Gene(s)" refers to the total geneset whose expression 1) was regulated 
down (negative), at a minimum of 5 fold by 17α-AED and/or regulated up (positive), at a 
minimum of 5 fold by 17β-AED and 2) resulted in a total difference in gene expression that is, at a 
minimum, an order of magnitude) between 17α-AED downregulated and 17β-AED upregulated 
expression of that gene. Because 17α-AED and 17β-AED are chemically identical this 10 fold or 
greater significance indicates that this expression may be related to the opposing biological 
functions of survival or irreversible cell death. We have identified 26 target genes in human T98G 
glioma cells (Table 4).  
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 TABLE 4: 17α-AED/17β-AED Target Genes in T98G glioma cells   
           
GENE  GENE BANK 
ID 
DESCRIPTION  17α-AED 17β-AED 
            
BMP2 NM_001200 bone morphogenetic protein 
2 
  <5 >5 
BRCA1 NM_007294   breast cancer 1, early onset      <5 >5 
CCL2 NM_002982 chemokine(C-C motif) 
Ligands 2 
  <5 >5 
CTSD NM_001909   cathepsin D   <5 >5 
CDKN1A NM_000389   cyclin-depensdent 
kinaseinhibitor 1A(p21, 
Cip1) 
  <5 >5 
CDKN2D NM_001800   cyclin-dependent Kinase 
inhibitor 2D(p19, inhibits 
CDK4) 
  <5 >5 
CDK2 NM_001798   cyclin-dependent kinase 2   <5 >5 
CSN2 NM_001891  casein beta   <5 >5 
EGFR NM_005228   epidermal growth factor 
receptor 
  <5 >5 
EGR1 NM_001964   early growth response 1    <5 >5 
GADD45A    NM_001924   growth arrest and DNA-
damage-inducible, alpha 
  <5 >5 
GYS1 NM_002103   glycogen synthase 1(muscle)   <5 >5 
HOXB1          NM_002144   homeobox B1                        <5 >5 
ICAM1 NM_000201 intercellular adhesion 
molecule 1 
  <5 >5 
IGFBP4 NM_001552   insulin-like growth factor 
binding protein 4 
  <5 >5 
IRF1 NM_002198   interferon regulatory factor 1   <5 >5 
JUN NM_002228  jun proto-oncogene    <5 >5 
NAB2 NM_005967 NGFI-A binding 
protein2(EGR1 binding-
protein 2) 
  <5 >5 
NFKBIA NM_020529 nuclear factor of kappa light 
polypeptide gene enhancer in 
B-cells inhibitor, alpha 
  <5 >5 
ODC1 NM_002539   ornithine decarboxylase 1   <5 >5 
PMEPA1 NM_020182   prostate transmembrane 
protein, androgen-induced 1 
  <5 >5 
TP53 NM_000546 tumor protein p53   <5 >5 
TP53I3 NM_004881  tumor protein p53 inducible 
protein 3 
  <5 >5 
WNT1 NM_005430 wingless-type MMTV   <5 >5 
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 General Discussion  
 Tumor cells are embedded in a hostile environment that is constantly challenged by 
chronic metabolic stress conditions that favor the activation of adaptive mechanisms in response 
to stress which includes autophagy [201][202]. The surrounding environment can influence the 
type and amount of protein that need to be folded in the ER. Unfolded protein responses (UPR) 
are initiated when misfolded proteins are sensed in the endoplasmic reticulum (ER). Previously it 
was shown that the same agent, the neurosteroid, 17α-AED can induce irreversible type I cell 
death (apoptosis) in myeloid cells and type II cell death in human glioma cells (autophagy) 
[154].   
 It was shown that 17α-AED-induced autophagy in T98G cells occurred through a 
specific partial unfolded protein response (UPR) [161] where the mechanism appeared to evolve 
from PERK activation and proceed to the phosphorylation of the eukaryotic translation initiation 
factor 2α. Specifically, elF2α phosphorylation was shown to induce CHOP (CCAAT/enhancer  
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Figure 12. General Mechanism of Autophagy Induction by 17α-AED 
 
 
binding protein homologous protein (CHOP) and the ER chaperone proteins such as glucose-
regulated protein of 78kDa (GRP78)) [161]. The response was also shown to be independent of 
the double stranded RNA-activated protein kinase (PKR) and the general control non-
derepressable 2 (GCN2) protein kinase [161]. These molecular events ended in the induction of 
beclin-1 and microtubule light chain 3 (LC3) cleavage resulting in irreversible autophagy. Thus, 
in TG98 Glioblastoma 17α-AED induces an unfolded protein response through PERK activation 
with resultant autophagy (Figure 12). 17β-AED, the chemically identical epimer, appears to 
produce a different response that results in survival.   
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 Autophagy ensues when beclin-1 forms a complex with Vps34 (PI3KClass III) [203]. 
BCL-2 prevents autophagy by forming a mutually exclusive complex with beclin-1 through the 
BH3 domain and inhibiting beclin-1 [204]. BCL-2 is an anti-apoptotic member of the BCL-2 
 family which binds to the outer membrane of the mitochondrion and serves to sequester BH3-
only proteins through direct binding. BCL-2 acts as a shield against these BH-3 only pro-
apoptotic agents which attack and destabilize the mitochondrion [205]. When BCL-2 cannot 
effectively bind beclin-1 then beclin-1 forms a complex with Vps34 (PI3KClass III) which 
activates membrane nucleation with ensuing autophagy [203].  
 Network analysis revealed that breast cancer early onset (BRCA-1) and BCL2 were main 
hubs that were directly associated in Network 1 (most significant) which demonstrate their main 
role in T98G stress response directed by 17α-AED and 17β-AED. Network analysis also 
demonstrated that GADD45 and IRF-1 were clustered together in network 4 while CDKN1A 
was clustered in network 2. These observations indicate that while CDKN1A, GADD45 and 
IRF-1 are BRCA-1 targets they are separated functionally from BRCA-1 by association with 
different genes.  
 17α-AED induces CHOP which is known to downregulate BCL-2 expression [161][206]. 
17α-AED downregulated both BCL-2 and BRCA-1 suggesting that the biological response 
initiated by 17α-AED extends beyond downregulation of BCL-2. Conversely, 17β-AED 
upregulated both BCL-2 and BRCA-1. Overexpression of BRCA-1 was shown to produce an 
apoptotic phenotype and correlated with GADD45 production [207]. 17β-AED upregulated 
BRCA-1, CDKN1A, GADD45 and IRF-1 and did not produce cell death. These are target genes 
that are associated with DNA repair, cell cycle regulation and immunity [208]. Upregulation of 
these genes have been shown to be BRCA-1 dependent [209][210]. CDKN1A expression, 
however, is not always obtained in the presence of BRCA-1 [211].  
61 
 Recently, it was shown that BCL-2 co-localizes with BRCA-1 to the mitochondrial and 
endoplasmic reticulum endomembranes [41]. BCL-2, while protective, will oppose genome 
 stability by binding to and preventing nuclear localization of BRCA-1 which results in an 
apoptotic phenotype [41]. BCL-2 will preferentially bind to Beclin-1 and inhibit autophagy 
[212]. Subsequently, the GADD45, CDKN1A and IRF-1 upregulation by 17β-AED indicates 
nuclear BRCA-1 activity despite upregulated BCL-2. 17α-AED directs a downregulation of 
BRCA-1 and BCL-2, thus targeting the beclin-1/Vps34 interface and irreversible autophagy 
(Figure 13). BRCA-1 is considered a tumor suppressor. Downregulation of BRCA-1 with 
activation of irreversible cell death demonstrates that while BRCA-1 is involved in these 
processes it is not required to achieve cell death.  
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Figure 13. Stress Induced Responses Directed by 17α-AED and 17β-AED 
63 
A) Specific 17α-AED-directed, PERK activated stress response leading to autophagy B) BRCA-
1 and BCL-2 are induced by 17β-AED leading to autophagy inhibition, DNA repair, growth 
control, immune response and survival. Double slash // indicates a complex. 
 The regulated expression of CDKN1A by BRCA-1 has been shown to occur in p53 dependent 
and independent manner. p53-independent induction of CDKN1A may occur through an 
interaction that occurs through a binding interaction of BRCA-1 with C-terminal binding protein 
(CtBP) and retinoblastoma binding protein 8 (CtIP) [213]. This interaction  normally inhibits the 
activation of BRCA-1 but in the presence of stress BRCA-1 is released from this inhibitory 
interaction to activate gene transcription [213]. In another study, it was shown that BRCA-1 
augments the p53 transcription factor but selectively induces genes involved in DNA repair and 
arrest of the cell cycle but not genes that direct apoptosis for target gene induction [214]. The 
absence of apoptosis from 17β-AED induced CDKN1A suggests that the main function of 17β-
AED in T98G cells depends on BRCA-1 in a p53-dependent way (Figure 14).  
 Further support is demonstrated by the 17β-AED directed upregulation of BRCA-1, p53, 
GADD45 and TP53I3 (PIG3) which indicates the stabilization of p53 with expression of DNA 
repair genes.  Importantly, this is occurring in the presence the p53 dual mutation that is present 
in T98G cells [193][194]. Interestingly, these observations may indicate a role for 17β-AED in 
BRCA-1 mediated tumor suppression.  
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Figure 14.  BRCA-1 directed, p53 dependent transcriptional response induced by 17β-
AED. 
A) BRCA-1 directed, p53 independent transcriptional response induced by stress.  B) BRCA-1 
directed, p53 dependent transcriptional response induced by 17β-AED. 
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 We show that 17β-AED and 17α-AED regulated p53 in an opposing manner). Network 
analysis of 17β-AED and 17α-AED target genes demonstrated that AKT was the central 
signaling hub of the top ranked network indicating its importance and significance.  The Wnt 
 pathway was previously shown to act in conjunction with AKT to stimulate phosphorylation and 
inactivation of GSK3B [215]. 17α-AED downregulated WNT1 thus supporting activation of  
 
Figure 15. Opposing Regulation of p53 Expression Induced by 17α-AED or 17β-AED 
through WNT1, AKT and GSK3β. 
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 GSK3B. Additionally, activation of PERK by 17α-AED also supports the activation of GSK3B 
kinase further reinforcing the reduction of p53 [216]. Conversely, 17β-AED upregulated p53 and 
WNT1 and the latter is known to decrease the activity of GSK3B through canonical WNT 
signaling [217]. Thus, this evidence suggests that 17β-AED opposes the action of 17α-AED by 
influencing the expression of WNT1 and subsequently influencing the AKT/GSK3B axis 
resulting in the opposing transcription of p53 (Figure 15). 
 Network analysis demonstrated that the target molecules of AKT in the dataset (BCL2, 
BMP2, CCL2, CDK2, CDKN1A, CSN2, EGR1, and TP53) were inconsistent with predicted 
findings for gene expression induced by 17β-AED and 17α-AED. Furthermore, the predictions 
of AKT target molecules were also opposing demonstrating that AKT is modulated by both 
steroids.  It is important to mention that the PTEN tumor suppressor is mutated in T98G cells 
[193]. This mutation is important twofold. First, PTEN is a tumor suppressor that induces 
autophagy [218] and second, PTEN can do this by activating the PERK/elF2α independently of 
its phosphatase activity [219]. This demonstrates that 17α-AED induces irreversible autophagy 
through PERK and elF2α independently of PTEN. It is unclear at this point if the PTEN mutation 
in T98G cells affects the BRCA-1 directed, p53 dependent response induced by 17β-AED. 
 An important observation from the microarray is that 17β-AED induced upregulation of 
both CDKN2D and p53. A p53 core regulator complex composed of MDM2, p53, CDKN2A and 
E2F was shown to regulate genes controlling G1-S and G2-M cell cycle arrest, apoptosis, 
inhibition of angiogenesis /metastasis and DNA repair (Figure 16A) [220]. CDKN2A and/or 
CDKN2D will bind to and inactivate MDM2, a ubiquitin ligase that will ubiquitinate p53 
resulting in increased levels and stabilization of the p53 protein  
 
67 
 
  
 
Figure 16: Core Regulatory Unit Governing Cell Cycle Arrest, Apoptosis, Inhibition of 
Angiogenesis and Metastasis and DNA Repair 
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A) Normal Core Regulatory Unit B) T98G core regulatory unit disrupted by mutations in p53 
and CDKN2A C) 17β-AED induced CDKN2D partially restructures the core regulatory unit D) 
17α-AED downregulates p53 and CDKN2D disrupting the core regulatory unit leading to the 
induction of irreversible autophagy.  
 [221][222]. CDKN2A and/or CDKN2D complexes are positively regulated by E2F1[223]. 
CDKN2A is deleted in T98G cells which affects the CDKN2A/p53 axis as well as CDKN2A/Rb 
axis (Figure 16B).  
.   DNA damage will activate p53 but not CDKN2A/CDKN2D [ 224][225].  Thus, 17β-
AED and not DNA damage upregulated CDKN2D to restructure the p53 core regulatory unit 
(Figure 16C). CDKN2A is associated with tumor suppressor functionality through p53 
dependent apoptosis whereas CDKN2D is not [226][227]. However,  p53-negative cell lines are 
resistant to CDKN2D-induced growth arrest [225]. Furthermore, loss of CDKN2D in the 
presence of functional CDKN2A results in tumors early in life [225]. Together, these 
observations demonstrate that some functionality is restored to the p53 core regulatory unit 
through CDKN2D.  However, at this point it is unclear how the functionality is affected because 
CDKN2A is deleted in T98G cells. In contrast to 17β-AED, 17α-AED downregulated p53 and 
CDKN2D. These observations demonstrate that 17α-AED influences the p53, CDKN2D and 
E2F core regulatory unit by downregulating p53 and CDKN2D while 17β-AED restructures this 
core regulatory unit through upregulation of p53 and CDKN2D.  
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 Free E2F is a link between p53 and the retinoblastoma tumor suppressor (Rb) [227]. The 
cell cycle normally progresses when Rb is inactivated by phosphorylation that is catalyzed by 
CDK-cyclin complexes [228][229]. Rb and E2F were associated with CDK2 (a target gene) in 
the core network analysis. CDK2 is present within the CDK-cyclin complexes that drive the cell 
through G1-S phases of the cell cycle. CDK2 is a central gene that is known to be necessary to 
facilitate the hyperphosphorylation of the Rb pocket after a priming phosphorylation by CDK4/6 
leading to the inactivation of Rb and the release of E2F and thus CDK2 is required for 
inactivation of the Rb protein [227].  
  17β-AED induces upregulation of CDK2 thus making it possible for the inactivation of 
Rb through CDK2-cyclin complexes. In opposition to 17β-AED, 17α-AED downregulated 
CDK2 and thus negatively influenced the primary phosphorylating complexes related to CDK2 
that would both drive the cell through G1-S and inactivate Rb by phosphorylation. It has been 
demonstrated that Rb-E2F is a rheostat that is modulated by phosphorylation thus playing an 
integral part in the induction of autophagy [230][231]. Here, we show that 17α-AED induced 
significant downregulation of CDK2, p53 and BCL2 transcription which is consistent with 
inhibition of the cell cycle, activation of the Rb complex and the strong induction of autophagy  
which was clearly demonstrated to occur (Figure 16D). Furthermore, it has been demonstrated 
that Rb/E2F plays a direct role in the regulation of Hox genes [232]. The fact that HoxB1 was 
identified as a target gene provides further support that RB/E2F is a target of 17β-AED and 17α-
AED. 
 Finally, free E2F produced through Rb phosphorylation has been shown to produce p53 
dependent apoptosis mediated through CDKN2A and p53 independent apoptosis mediated 
through TRAF2 [227]. This observation has two important implications. First, BIRC2 and BCL2 
are both 17β-AED target genes and thus, indicate the presence of anti-apoptotic genes that 
prevent death derived from the intrinsic and extrinsic pathways in T98G cells. Second, p53 
dependent apoptosis is not produced in T98G cells by either 17β-AED or 17α-AED. Therefore, 
17β-AED and 17α-AED influence the Rb-E2F rheostat; however, other additional cellular 
transcriptional controls coordinate and integrate the biological outcome. More studies will need 
to be performed to further elucidate the action and effects of the specific cell-directed stress 
responses induced by the presence of 17α-AED and 17β-AED  
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 Summary 
 Targeting cancer through main pathways is fraught with difficulties [233]. 17β-AED and 
17α-AED are chemically identical stereochemical epimers that differ only in the position of the 
hydroxyl at carbon 17 of the cycloperhydrophenanthrene ring structure (Figure 1). This report 
demonstrates, for the first time, that naturally occurring, chemically identical adrenal hormone 
(17β-AED or 17α-AED) treatments resulted in the induction of significant, specific yet 
differential transcriptional responses to stress that, despite the presence of major mutations, 
positively affected the core transcriptional regulatory unit in T98G cells as well as the three 
critical pathways inherent to Glioblastoma cells (Figure 17). 17α-AED treatment resulted in type 
II programmed cell death while 17β-AED treatment resulted in DNA repair and growth control. 
 Schematic diagram of the primary sequence alteration for components of the 
CDKN2A/MDM2/p53 axis, Ras/PI3K axis, and CDKN2A/CDK4/RB signaling pathways in 
T98G cells are shown. Light gray with black lettering indicates inhibiting genetic alterations in 
the T98G cells.  Dark gray with white lettering indicates a functional mutation differing from the 
wild-type. Block Crosses indicate the affected biofunction. 17β-AED affects the 
CDKN2A/MDM2/p53 axis by up regulating CDKN2D and p53. 17α-AED affects this axis by 
downregulating the mutated p53 and CDKN2D thus the activity of 17α-AED does not require 
the CDKN2A/MDM2/p53 axis. Both 17β-AED and 17α-AED affect the Ras/PI3K axis by 
modulating AKT. 17α-AED phosphorylates elF2α and thus does not require PTEN for this 
function. 17β-AED upregulates CDK2 while 17α-AED downregulates CDK2 and general 
translation.  Thus both hormones regulate the RB/E2F rheostat without the requirement of 
CDKN2A.  
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Figure 17: T98G Gene Mutations in 3 Critical Glioblastoma Signaling Pathways 
 
 These observations demonstrate that 17α-AED affects the 3 main signaling pathways 
without the requirement for the mutated genes in these pathways resulting in irreversible cell 
death while 17β-AED induces a cell-directed transcriptional program targeting DNA repair and 
growth control despite the presence of the mutations in these 3 pathways
 
 CHAPTER 4: Pressure Ulcers in Patients with Spinal Cord Injury; Microarray and Network 
Analysis 
 
 
 
 
Introduction 
 Chronic non-healing wounds, primarily pressure ulcers, are a major clinical challenge in 
the long-term care of patients with spinal cord injury. Clinical evidence demonstrates that 
chronic pressure ulcers are a major source of morbidity and mortality, having a significant 
impact on spinal cord injury (SCI) patients’ health and health care resource expenditures.  
Chronic pressure ulcers may potentially occur in any SCI (spinal cord injury) patient, as a result 
of denervation of skin below the lesion level and impaired mobility.   
Wound healing is a multifactorial process which has been elucidated by state-of-the-art 
wound care research.  Regulation of normal wound healing depends largely on the interactions 
among multiple cell types, which includes immune cells (neutrophils, monocytes, lymphocytes 
and dendritic cells), endothelial cells, keratinocytes and fibroblasts.  Those cells undergo marked 
changes in gene expression and phenotype, leading to cell proliferation, differentiation and 
migration [234-236].  If this response is successful, these processes will be shut down in a 
precise sequence in the ensuing days as healing progresses [235]. 
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 In SCI patients, a common and frustrating occurrence is the frequency of skin 
breakdown, particularly under bony prominences. A further problem with skin breakdown in 
persons with SCI is the slow healing rates (sometimes in excess of 1 year) in comparison with 
wounds in other 
 clinical scenarios.  Over the past 30 years, research has been performed to try to uncover 
metabolic and physiological differences between the skin above and below the level of the SCI 
[237].  In SCI related chronic pressure ulcers, the normal healing process is significantly altered 
and delayed, which may result from multiple physiologic deficiencies in denervated skin.  
Several studies have shown that molecular events may be the crucial factors resulting in collagen 
and extracellular matrix (ECM) depletion, decreased activity and migration of fibroblasts, and 
wound-healing delays [237-242]. However, the precise biologic processes involved in prolonged 
SCI-related wound healing are still not completely understood. 
Microarray technology has been utilized to examine the expression of a large number of 
genes in an experimental condition simultaneously [243].  It has been problematic, however, to 
ascertain biological meaning from the use of microarray alone.  Here we utilize whole genome 
microarray and IPA® network analysis to identify genes that are different and biologically 
significant between chronic SCI related pressure ulcers and normal skin controls. In order to 
further characterize the transcriptional program within the chronic pressure ulcer edges, we 
applied targeted network analysis of known stress related genes that are transcriptionally 
regulated by androstene hormones to identify core transcriptional regulators associated with 
chronic pressure ulcer and the normal skin controls genes. These results provide a new 
understanding of the molecular mechanisms that differentiate chronic pressure ulcers from 
normal skin during wound healing.  
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 Materials and Methods 
Protection of Human Subjects 
The study was approved by the Investigative Review Board Human Subjects 
Subcommittee at the Dallas VA Medical Center and was conducted in accordance with its 
regulations.  To minimize risk of disclosure to others and discrimination or stigmatization, 
measures were taken to ensure confidentiality.  Each participant was assigned a confidential code 
number to be used by staff when collecting and reporting information.  Research staff used coded 
forms and confidential code numbers for study participants when collecting and processing test 
data. Laboratory samples and results were identified only by confidential code numbers.  At no 
time did the project release medical or laboratory information that could in any way be linked to 
a particular study participant.  All data used in this transcript for publication of the findings from 
the study were presented in aggregates and without the identities of individual participants.  
 
Recruitment and consent procedures  
Six males, aged 20 -70, with paraplegia or tetraplegia hospitalized with chronic pressure 
ulcers in a VA SCI center were selected for this research.  All patients were receiving at least 
daily dressing changes according to their inpatient wound care orders. Explanation was given to 
patients who participated in the study and any questions or concerns they might have during the 
study were addressed as well.  A formal written consent form was given to them to read.  All 
subjects signed the IRB-approved consent form prior to any interventions taking place. Time was 
provided for review so that the client could share his intention to participate with significant 
others or family members prior to enrollment.   
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 Specimens  
Two or more skin specimens, about 100 mg each, were excised using a scalpel from each 
of six patients. One or more samples were taken directly from the edge of the wound and another 
from normal skin above the neurologic level of injury (suprascapular region). All samples were 
removed immediately upon excision. Six edge specimens were obtained in patients who had 
pressure ulcers which lacked viable granulation tissue, i.e. had a flat, smooth appearance. All 
specimens were put in 5ml of RNA later (Ambion) solution and kept in refrigerator before 
submission for RNA extraction.  Both normal and wound tissues were de-identified prior to 
transporting to the lab for further analysis. 
 
Total RNA Extraction from Skin Tissues 
Total RNA was isolated from skin specimens using the Lipid Tissue mini kit (Qiagen) 
according to manufacturer’s instructions.  Briefly, 100mg tissue was homogenized in 1ml 
QIAzol Lysis Reagent.  After addition of 200μl chloroform and shaking by hand, the 
homogenate is separated into aqueous and organic phases by centrifugation.  The upper, aqueous 
phase is transferred to another tube, and an equal volume of ethanol is added to provide 
appropriate binding conditions. The sample was then applied to the RNeasy spin column, where 
the total RNA bound to the membrane and phenol and other contaminants were efficiently 
washed away.  High-quality RNA was then eluted in 100μl RNase-free water.  The RNA 
concentration was measured by Spectrophotometer (Nano Drop) and RNA quality was checked 
by Bioanalyzer (Agilent Technologies Inc., Palo Alto, CA). 
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Microarray analysis using Illumina Human-6 BeadChip arrays 
a. cRNA amplification and probe labeling: cRNA was amplified and labeled with biotin 
for each sample using MessageAmp II-biotin enhanced kit according to manufacturer’s manual 
(Applied Biosystems).  Briefly, 200ng total RNA was used for the double strand DNA synthesis 
with T7-oligo (dT) primer and followed by in vitro transcription (IVT) reaction to amplify cRNA 
and incorporate biotin into the synthesized cRNA probe.  The cRNA probe was then purified and 
quantified by Spectrophotometer.  Three labeling replicates were done for each sample. 
b. Illumina Human-6 BeadChip hybridization: Biotinylated cRNA probe was hybridized 
to the Illumina Human-6 BeadChip Arrays (Illumina, Inc., San Diego, CA), 1,500ng labeled 
cRNA was used for hybridization for each array.  The hybridization, washing and scanning were 
performed according to the manufacturer’s manual instruction.  A total of 36 arrays were used 
for 12 samples (each sample has 3 replicates). Network analysis was performed on these whole 
genome microarrays and the microarray expression data for the 16 genes identified in the most 
significant network are represented in Table 5. Additional information on the genes associated 
with UBC and that are unique to normal skin edges in network 1 can be found in Appendix 4A. 
Additional information on the genes associated with UBC that are unique to chronic pressure 
ulcers in network 1 can be found in Appendix 4B. Information on UBC-associated genes that are 
shared by normal skin and chronic pressure ulcer can be found in Appendix 4C.
 
 
 
 
 
 Table 5: Whole Genome Microarray Network Analysis: Ubiquitin C-centered Networks 
       Normal skin and chronic pressure ulcer raw data represent the average fluorescence signal intensity measured in fluorescence units [244]. 
Positive fold change is an increase in signal intensity from the skin control to the chronic pressure ulcer and is calculated as the chronic pressure 
ulcer fluorescent units divided by the skin control fluorescent units. Negative fold change is a decrease in signal intensity from the skin control to 
the chronic pressure ulcer.  
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 Microarray data analysis 
The microarray data were extracted using BeadStudio v3.1 software provided by the 
manufacturer.  The data were background subtracted and normalized using Cubic Spline 
algorithms.  Statistical analysis was performed by comparing the samples between each group 
using the Student’s t test with the Bonferroni Correction.  All samples and replicates within each 
category were pooled as a group.  
  
Network Analysis 
Network Core Analysis 
 An Ingenuity IPA® core analysis was performed where the identified target genes were 
overlaid onto a global molecular network developed from information contained in the IPA 
database. The Ingenuity Knowledge Base Includes: Data Sources scanned included Ingenuity 
expert findings®, mi records, TaRbase, TargetScan Human, BIND, BIOGRID, Cognia, DIP, 
INTACT, Interactome studies, MINT, MIPS, ClinicalTrials.gov, GeneOntology, GVK 
Biosciences, Kyoto Encyclopedia of Genes, miRBase and the Obesity Gene Map. 
 
Network Statistics (Score) 
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 The network score is a numerical value used to estimate how well the network eligible 
genes match the Ingenuity Knowledge Base genes. The score takes into account the total number 
of network eligible molecules, network size, and the total number of possible associated 
molecules in the Ingenuity Knowledge Base.  The Network Score is based on the hypergeometric 
distribution and is calculated with the right-tailed Fisher's Exact Test. For example, a network of 
35 molecules has a Fisher Exact Test result of 1x10-8. The network’s Score = -log (Fisher's Exact 
 test result) = 8. This is interpreted as there is a 1 in a 100 million chance of obtaining the 35 
molecule network containing network eligible molecules randomly that could be in networks 
generated from the Ingenuity Knowledge Base.  
Core regulator Analysis of Chronic Wounds 
 To evaluate and identify associations with core transcriptional regulators involved in 
stress we analyzed each gene that was different between the UBC centered Network 1 of the 
Normal Skin Control and the UBC centered Network1 of the Chronic Pressure Ulcer by running 
individual IPA®core analyses of each gene, its known binding partners identified in Ingenuity® 
and known ER (endoplasmic reticulum) stress sensors (ERN1, PERK, and ATF6)[245], and 
known genes associated with programmed cell death (PI3KC3, beclin-1, SQSTM1)[246].  
 Δ5-androstene-3β, 17α-diol (17α-AED) has been shown to produce definitive type II 
programmed cell death in T98G cells [157]. The mechanism whereby 17α-AED induces 
oncophagy in T98G cells has previously been identified and described [195][196]. Δ5-
androstene-3β, 17β-diol (17β-AED) is the epimer of 17α-AED. These naturally produced adrenal 
hormones are chemically identical and differ only in the stereoisomeric position of the hydroxyl 
group located at carbon 17 of the steroid ring structure. 17β-AED, in opposition to 17α-AED, 
does not produce cell death in T98G Glioblastoma cells [196]. 17β-AED, in fact, promotes 
significant biological effects including the enhancement of the immune system [81][197] even in 
the presence of glucocorticoids [112][109] and provides protection against lethal radiation [198].  
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 We have prior shown that these two androstene hormones regulate 26 genes related to 
regulation of ER stress which include or are associated with core transcriptional regulators. 17α 
and 17β-AED regulate these genes in an opposing manner that is at least 1 order of magnitude 
different. Thus these 26 genes are intricately involved in the modulation of the stress response 
 and these 26 genes (Table 3) represent a set of regulatory genes that are involved in the cell 
directed decision to upregulate immunity, repair genomic material or self destruct through 
programmed cell death mechanisms. Both 17β-AED and 17α-AED regulated a specific cell 
directed response to stress. Because Chronic wounds represent a stressed cellular environment it 
was imperative to evaluate the transcriptional regulation of the 26 genes and identify the 
association of these core regulators with genes that were identified as significant from the 
network analysis of the whole genome array within the chronic wound edges.  
 
Results and Discussion 
 Chronic pressure ulcers represent a stressful environment for the cells residing there. 
Environmental changes cause cells to alter collections of expressed proteins in order to maintain 
homeostasis. Protein expression patterns are known to be modified in stressed conditions through 
transcriptional, translational and post-translation mechanisms [247]. Cellular functions including 
cell survival, death, proliferation, differentiation are realized through the transcription, 
translation and degradation of large multi-protein complexes. The modular components must 
either be sustained or degraded based on cellular control. It is now understood that the cellular 
timescale does not always apply to the abrupt appearance or disappearance of the rate limiting 
components of transcription and translation molecular "machinery". The ubiquitin proteosomal 
system, by regulating activating and deactivating regulators through post-translational 
degradation of cellular proteins, centrally orchestrates cellular functions [248]. 
81 
 Ubiquitin is a highly conserved protein consisting of 76 amino acid that targets substrate 
proteins for degradation through the 26S proteosome [11]. The ubiquitin proteosomal system has 
emerged as the principal system of protein fate inside cells [249]. Ubiquitination can result in 
 degradation of native correctly folded proteins for the purpose cellular process control including 
transcription, signal transduction and development [250]. However, ubiquitination can also 
degrade unfolded or misfolded proteins in the endoplasmic reticulum (ER) through a process 
termed Endoplasmic Reticulum Associated Degradation (ERAD). Protein folding is inherently 
error prone. In addition, many variable stress stimuli such as hypoxia, bacterial infection, 
repetitive ischemia/reperfusion and altered cellular and systemic stress responses bear on chronic 
pressure ulcers and may compromise the rate or efficiency of protein folding [251][252].  
 Proteins are assembled in the endoplasmic reticulum and secreted proteins are subjected 
to ER quality control [253]. When proteins attain their native conformations they may be 
directed to their final destination. When proteins do not achieve their native conformations they 
are subjected to further processing to achieve proper folding. If the proteins do not achieve their 
native conformation after ER quality control processing then they are subjected to ERAD [254]. 
ERAD is a complex process and proteosomal degradation can occur with mechanisms outside 
the ubiquitin pathway, however ubiquitination is the major mechanism associated with 
degradation of proteins through the proteosome [252].  
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 It is well established that attachment of ubiquitin occurs through a cascade of three 
enzymes; E1 (ubiquitin activating enzyme), E2 (ubiquitin conjugating enzyme), and E3 
(Ubiquitin E3 Ligase) [252][255]. Activation of ubiquitin by E1 initiates the process. Then the 
activated ubiquitin is transferred to the E2 and finally the E2 conjugate associates with the E3 
ligase and the E2/E3 complex transfers the ubiquitin to a lysine in the protein target [256].  The 
specific combination of E2 and E3 enzymes determines the chain linkage type [257]. Ubiquitin is 
the common denominator for proteosomal, lysosomal and autophagosomal degradation [257]. 
  The IPA® core analysis was performed on the whole genome microarray as described. 
The normal skin microarray and the chronic wound microarray each produced 25 individual, 35 
gene networks. Investigation of the core analysis showed that the major network (most 
significant) for both the normal skin control (Score: 36) and the chronic pressure ulcer (Score: 
36) was ubiquitin C centered. Ubiquitin C is an E2 enzyme  that has been shown to be a part of 
evolutionarily conserved E2/E3 complexes [250]. Normal skin and chronic wound networks 
were 77% similar with 27 identical genes and 8 different genes associated with UBC (Figure 18).  
 CERCAM (cerebral endothelial cell adhesion molecule), LMF2 (Lipase maturation factor 
2), SLC22A17 (solute carrier family 22 member 17), UBAP1 (Ubiquitin associated protein1), 
RNF145 (ring finger protein 145), and C8orf76 (chromosome 8 open reading frame 76) were all 
upregulated in the chronic pressure ulcer as compared to the normal skin control. CLIP3 (CAP-
GLY domain containing linker protein 1) and RNF24 (ring finger 24) were the only genes that 
were not transcriptionally affected, however CLIP3 and RNF24 became associated with 
Ubiquitin C in network 1 of the chronic pressure ulcer (Table 5) indicating a functional shift 
involving the association between UBC and these genes. In general, it can be stated that these 
eight genes are associated with Ubiquitin C (UBC) in the chronic wound and may represent 
treatment targets or treatment indicators in these currently difficult-healing chronic pressure 
ulcers.  
83 
  Six of the eight different genes in the normal skin control (Figure 18) possessed 
transcriptional differences (Table 6.). Additional gene information can be found in Appendix 2 
and 3. Of the eight genes, only NCCRP-1 (non-specific cytotoxic cell receptor protein 1 
(zebrafish)) was upregulated in the chronic pressure ulcer. KPRP (keratinocyte proline rich 
protein) and RILPL1 (Rab interacting lysosomal protein-like 1) did not have significant 
 expression changes. DEF8 (differentially expressed in FDCP 8 homologue (mouse), THUMPD1 
(THUMP domain containing 1), MMGT1 (membrane magnesium transporter 1), BEX4 (Brain 
expressed X-linked 4), and SECISBP2L (SECIS binding protein-2 like) were all slightly 
downregulated. These findings imply a loss of normal skin functionality related to these UBC-
associated genes. 
 
 
                       A) Skin Control                                                   B) Chronic Pressure Ulcer 
 
Figure 18. Network schematic of genes that are associated with UBC in the A) the normal 
skin network #1 or B) the chronic pressure ulcer network #1. These genes are present in both 
the normal skin and the chronic pressure ulcer. The 8 genes associated with UBC in the chronic 
pressure ulcer are not associated with UBC in the normal skin and the 8 genes associated with 
UBC in the normal skin are not associated with UBC in the chronic pressure ulcer.  
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  Cerebral Endothelial Cell adhesion Molecule (CERCAM) is a gene that is significantly 
associated with UBC only in the chronic pressure ulcers. This gene is widely transcribed in the 
nervous and secretory tissues including salivary gland, pancreas, liver and placenta [258]. 
CERCAM has been shown to be a glycosylated binding partner of Fbox06 [259]. CERCAM is 
related to CoLGALT1 and CoLGALT2 but does not possess the ability to glycosylate collagen 
and  it possesses an ER localization signal and localizes to the ER like COLGALT1 and 
COLGALT2 [258]. CERCAM was first described as a cerebral adhesion molecule and bound to 
CDllb/Cd18 and was suggested to be involved in leukocyte trafficking which is associated with 
inflammatory processes [260]. It is unknown whether this protein glycosylates different proteins 
other than collagen [261].  
 CERCAM was mapped to a genetic locus in the wrinkle free mouse (wrfr), an autosomal 
recessive mouse mutation that results in extremely tight, thick skin [262]. Interestingly, the 
wrinkle-free mice die shortly after birth and the phenotype is similar to restrictive dermopathy 
[262]. Taken together, these observations suggest that CERCAM is associated with a defective 
skin barrier while facilitating leukocyte trafficking and that these processes are associated with 
Fbox06 related ubiquitination processes in the chronic pressure ulcers of SCI patients.   
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 CERCAM was found to be upregulated (2.89 Fold, p < 0.001) in the chronic pressure 
ulcers (Table 5.). Targeted core and stress regulator network analysis demonstrated that 
CERCAM associated with p53 and CDK2 through UBC and SQSTM1 suggesting that these core 
regulators may influence the expression of CERCAM and the SQSTM1-p53 association may 
influence the UBC-CERCAM interaction and influence the stress response and/or survival 
decision made by the cells.  
  LMF2 (lipase maturation factor 2) is another gene that, similarly to CERCAM is a 
glycated FboxO6 binding partner [259]. LMF2 is slightly yet significantly upregulated (1.23 
Fold, p< 0.05) in the chronic wound. This further supports a role for FboxO6 in ubiquitin 
regulation of proteins in the chronic pressure ulcer. FboxO6 is associated with ubiquitination and 
degradation of glycated proteins in a process termed GERAD (Glycated Endoplasmic Reticulum 
Associated Degradation) [263]. The significant association of FboxO6O associated genes with 
UBC may point to the importance of ubiquitination of glycated proteins in the CPU. 
 LMF2  was originally identified as a potential gene involved in lipid metabolism [264]. 
LMF2 is 42% homologous to LMF1, however, LMF2 cannot complement or rescue LMF1 
deficient cells suggesting a different role for LMF2 [264]. While a physiologically relevant and 
non-redundant role was suggested for LMF2, there is no further information about this gene 
available.  
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 Little is known about the function of RNF145 although it was found to structurally 
cluster closest with RNF139 (TRC8) with both RNF proteins containing multiple membrane 
domains [265]. RNF145 is a putative human transmembrane RNF protein [266][265].  RNF 
domains are composed of 40-80 amino acids and contain eight conserved cysteine and histidine 
residues that chelate two zinc ions to form a cross-brace structure which allows correct folding 
and function of the RING [266][265]. RNA domains have 3 classifications based on the structure 
of the finger: C3H4 (RING-HC), C3H2C3 (RING-H2) or C4HC3 (RING-CH or RINGv). RNF 
145 possesses the C3HC4 (RING-HC) RNF domain.  The RNF domain is a scaffold for binding 
to E2 enzymes closely with substrate proteins which allows for efficient transfer of ubiquitin to 
substrate proteins [267].  
  Ring Finger 145 (RNF145) was found to be significantly upregulated (1.82 Fold, p < 
0.001) in the chronic pressure ulcers (Table 5.).  Humans possess an expanded repertoire of E3 
Ligases that are available to accomplish ERAD [268]. RNF 139 was found to be an E3 Ligase 
that is involved in ERAD of normal and abnormal proteins and intriguingly, this multi-function 
ligase is targeted by a human CMV virus protein which results in ubiquitination and destruction 
of MHC I [268]. In a similar fashion, the high structural similarity of RNF145 to RNF139 
suggests that this E3 ligase is involved in ERAD within the CPU.   RNF 145 function and 
interactions have not yet been characterized yet RNF 145 upregulation along with UBC 
association in the chronic pressure ulcer demonstrate that RNF145 may play a role in 
proteosomal protein degradation. Individual analysis of RNF145 in relation to targeted core and 
stress regulators associated p53 with RNF145 through UBC. These observations imply that 
RNF145 may be functionally associated with p53 directed processes within the chronic pressure 
ulcer. 
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 UBAP1 is another transcriptionally regulated gene (1.53 fold, p<0.001), UBAP1 
(ubiquitin associated protein 1) is a component of endosomal sorting complex 1 (ESCRT1) and 
is associated with Vps28, Vps37A and TSG101 [269][270].  The ESCRT system has been well 
described [271-274]. ESCRTS are multi-protein complexes that function in the biogenesis of 
multi-vesicular bodies [272]. UBAP1 forms a heterotimeric protein complex that contains 
multiple ubiquitin binding domains with Vps28, Vps37A and TSG101 allowing ESCRT1 to 
readily acquire ubiquinated membrane proteins cargos [269]. 
  
Figure 19. UBAP1 Related Core Master Transcriptional Regulator Network 
 
Genes above the large box represent members of the UBAP1 containing ESCRT1 system. 
ESCRT1 consists of Vps28, Vps37A, TSG101, and UBAP1. Known linkages of ESCRT1 with 
the main transcriptional regulators are through GCR (glucocorticoid receptor) and ERK1/2. 
Genes/histones to the right of the box represent known links to the transcriptional regulators. 
p300/CBP provides a linkage that unites all the transcriptional regulators within the large box 
containing the most significantly associated transcriptional regulators. The dotted line indicates 
the EGFR regulation by ESCRT1 through UBAP1. 
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 Membrane bound proteins are sorted through multi-vesicular bodies upon binding to ubiquitin. 
Ubiquitinated proteins are then recognized through a series of ESCRTs which contain multiple 
ubiquitin binding domains coordinate and complete the formation of intraluminal vesicles.  
 A salient feature of UBAP1 in this system is the linkage between UBAP1 and 
EGFR1degradation. UBAP1 was shown to be necessary and sufficient to degrade EGFR from 
the cell membrane via ubiquitin binding and lysosomal degradation [272][272]. EGFR signal 
transduction is well documented to boost immune and tissue repair abilities of damaged tissue 
[275-277]. Thus, loss of EGFR and its signal transduction abilities greatly alters the ability of the 
cells in the wound edge to respond with programs of tissue repair or immunity. EGFR 
transcription was also affected. EGFR was downregulated (-1.71 Fold, p<0.001)) in the CPU as 
compared to the normal skin control. Individual analysis of UBAP1 in relation to targeted core 
and stress regulators demonstrated a relationship with a set of core transcriptional regulators 
(Figure 4). UBAP-1 demonstrates how ubiquitin integrates proteosomal and lysosomal 
degradation; signal transduction and transcriptional regulation to obtain a biological response. 
The upregulation of UBAP-1, association of UBAP-1 with UBC in the chronic pressure ulcers 
with concomitant downregulation of EGFR transcription indicates transcriptional and possibly 
ubiquitin/proteosomal downregulation of EGFR in the chronic pressure ulcer. 
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 SLC22A17 is also a gene shown to have significant transcriptional regulation (in the 
chronic wound analysis. SLC22A17 (Solute Carrier Family 22, Member 17) is a 25kDa protein 
that belongs to the lipocalin superfamily. SLC22A17 is structured to uptake small lipophilic 
molecules including hormones, retinoids, arachadonic acid and fatty acids. SLC22A17 will 
transport its lipocalin 2 (LCN2) ligand either alone or bound to iron [278]. Transport of 
Lipocalin bound with iron leads to cell survival whereas unbound lipocalin leads to apoptosis 
 [279][280]. It was also shown that LCN2 had anti-microbial properties by sequestering iron 
away from invading bacteria [279].  
Previously it was demonstrated that BCR-ABL would influence the expression of LCN2 
and SLC22A17. BCR-ABL is a fusion protein that possesses constitutively active ABL tyrosine 
kinase activity promoting proliferation and survival [281]. BCR-ABL signaling caused a 
dysregulation of LCN2 and SLC22A17 where LCN2 was upregulated in BCR-ABL containing 
cells while SLC22A17 was not leading to an apoptotic effect on surrounding cells but allowing 
survival of transformed BCR-ABL cells. Overexpression of SLC22A17 was shown to induce 
apoptosis in transformed cell lines indicating that downregulation of SLC22A17 is critical for 
survival in the presence of LCN2 [282]. Together, these observations indicate that the presence 
of LCN2 with  
 In contrast to cells containing the BCR-ABL oncogenes, LCN2 in the chronic wounds 
was upregulated (2.31 Fold, p<0.001)) in conjunction with a slight upregulation in SLC22A17 
(1.22 Fold, P<0.05) (Table 5.). LCN2 was prior observed in wound fluid demonstrating that 
regulation of SLC22A17 is critical to cell survival [283]. While the cells and cellular 
mechanisms involved are unclear, upregulation of SLC22A17 has been shown to predispose 
cells with the SLC22A17 receptor to apoptosis through LCN2 while cells that downregulate 
SLC22A17 are protected from LCN2- induced cell death [284]. Targeted core and stress 
regulator network analysis demonstrated that SLC22A17 is associated only with UBC indicating 
an indirect relationship between SLC22A17, UBC and the core stress regulators and 
demonstrating the importance of ubiquitin in the regulation of this receptor. 
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LCN2 has been directly associated with non-healing chronic pressure ulcers [283]. 
Wound fluid from non-healing chronic venous pressure ulcers were shown to contain persistent 
 LCN2 levels with concomitant Toll-Like Receptor 2 and 4 activities [283]. Healing wounds 
demonstrated decreased Toll like receptor activity and LCN2 levels [283].  Since Toll-Like 
receptors are associated with innate immune responses then this implies that an abnormal innate 
immune response is related to the multifactorial environment present within the chronic wounds. 
Since 17β-AED and 17β-AET have been shown to possess innate immunity functionality 
associated with protection and survival in cells undergoing stress then it follows that these 
hormones may possess the ability to stimulate an effective innate immune response within the 
chronic wound [103,351]. 
 RNF24 is an E3- ubiquitin ligase that has been associated with Huntington's disease. 
RNF24 has a C3-H2-C3 (RING-H2) RNF domain [265],  is localized to the Golgi apparatus and 
was shown to interact with ankyrin-repeats domain(ARD) of TRPC (transient receptor potential 
channel) channels 1,3,4,5,6 and 7 [285]. RNF24 with its RING-H2 RNF domain was shown to 
not affect calcium channel-induced expression of RNF24, and did not affect the maturation 
process of TRPC6 and yet significantly reduced the cell surface expression of TRPC6 suggesting 
that RNF24 interacts with TRPC channels in the Golgi and affected intracellular trafficking 
[285]. Therefore, it is possible that UBC can affect cell secretion, contraction, growth, 
differentiation and apoptosis through the regulation of RNF24.  
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 Individual analysis of individual analysis of RNF24 in relation to targeted core and stress 
regulators associated p53, CTSD, GYS1, and PI3KC3 with RNF24 through UBC. These genes 
are well known for directing cell death programs in many different cell types 
[220][286][287][288][289][245]. Transcription of RNF24 is not significantly different between 
the CPUs and normal skin yet this E3 ubiquitin ligase becomes associated with UBC in the 
chronic wound suggesting a function for the UBC-RNF24 association in the chronic wounds. 
  CLIP3 (CAP-GLY domain containing linker protein 3) is a gene that codes for the CLIP-
170-related protein of 59 kDa and this protein is different than other CLIP proteins [290]. CLIP3 
is a gene related to apoptotic function and is not transcriptionally affected in the chronic pressure 
ulcers (Table 5). Recently, CLIP3 in conjunction with cylindromatosis turban tumor syndrome 
(CYLD) protein was shown to regulate RIP1 ubiquitination and promote caspase-8 activation 
and apoptosis in the context of TNFα signaling [291]. Upregulation of CLIP3 expression 
enhanced while CLIP3 silencing inhibited the apoptotic activity of CYLD [291]. It was proposed 
that CLIP3 in conjunction with CYLD accomplishes de-ubiquitination of RIP1 and subsequent 
apoptosis [291].  
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 CYLD was, however, downregulated (-2.14 Fold, p<0.001) in the chronic pressure ulcers 
while the CLIP3 expression change was insignificant. CLIP (cytoplasmic linker protein) proteins 
are associated with intracellular organization and movement through regulation of microtubules 
[292]. CLIP-3 differs from other CLIP proteins in that it does not bind to microtubules, is 
localized to the Golgi, contains a Golgi localization domain that is known to be necessary for 
addressing cytosolic proteins to the Golgi and is part of the trans-Golgi network [293]. 
Additionally it was noted that CLIP3 was associated with lipid rafts in HeLa cells and regulates 
AKT cellular compartmentalization by associating with phospho-AKT [290][294]. 
Overexpression of CLIP3 was shown to interfere with microtubules and thus CLIP-3 is thought 
to contain some anti-CLIP function thus perturbing intracellular organization and movement 
[290]. Thus, CLIP3 in the presence of downregulated CYLD may indirectly perturb the 
intracellular organization and movement of cells and thus the immune response present in the 
chronic pressure ulcer edges. 
   It should be noted that RIP1-mediated, pro-apoptotic signaling may be dependent 
on cell type and context [291]. Individual analysis of CLIP3 in relation to targeted core and 
stress regulators demonstrated that CLIP3 is mainly associated with RIP1 and TNFRSF1; 
however, UBC is associated with p53, CDK2 and cJUN. Thus these regulators may indirectly 
influence the activity of CLIP3 and may affect the cell death decisions of the cell(s).  
 NCCRP-1 (Non-specific cytotoxic cell receptor protein-1) was originally cloned from 
catfish, zebrafish, tilapia, gilthead bream and carp and was predicted to be either a Type II or 
Type III membrane receptor [295- 300]. Non-specific cytotoxic cells are the equivalent to natural 
killer cells in the teleost fishes [301]. NCCRP-1, however, was absent on the surface of cells and 
subsequently was found to contain homology with the F-box only proteins [302]. NCCRP-1 
activity was suggested to be responsible for immune functions of nonspecific cytotoxic cells in 
fish [295].  F-box functions include protein-protein binding of protein substrates in E3 ubiquitin 
multi-subunit ligases for subsequent ubiquitination by the ubiquitin proteolytic system [303].  
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 The microarray analysis indicated that NCCRP-1 was present in the most significant 
UBC network of the normal skin control; however, NCCRP-1 was upregulated (2.10 fold, 
p<.001) while the UBC association was lost in the chronic pressure ulcers, in chronic pressure 
ulcers (Table 5.). NCCRP-1 has been shown to have 5 paralogues in humans: FBX02, FBX06, 
FBXO17, FBX027 and FBX044 which  function as part of  E3 ubiquitin ligase complexes [304].  
Sequence alignments of  NCCRP-1 and structural interpretations suggested NCCRP-1 to be part 
of the lectin Type subfamily of Fbox proteins and it was suggested to be renamed as FBXO5O 
[302]. Fbox proteins have been shown to be present and impart functionality to E3 ubiquitin 
multi-subunit ligases [305][306][307]. Thus, upregulation of FboxO5O protein (NCCRP-1) and 
upregulation of FboxO6O-associated proteins and the lack of association of NCCRP-1 with UBC 
 in the chronic pressure ulcers suggest that the NCCRP-1-UBC association has lost significance 
in the chronic pressure ulcer. Upregulation of NCCRP-1 may indicate an individual functional 
role in the dysfunction of the chronic pressure ulcer.  
 Individual analysis of NCCRP-1 in relation to targeted core and stress regulators 
indicated that the core regulatory genes associated with NCCRP-1 are p53, CDK2, cJUN and 
ESR1 with indirect associations between ELAVL1 (discussed below) and UBC (Figure 3). These 
core transcriptional regulators may underlie the upregulation of NCCRP-1. Furthermore ESR1 is 
known to influence immune functions and its presence may indicate involvement with cJUN, 
p53 and ELAVL1 in the transcriptional regulation of NCCRP-1 [308]. The exact role of 
upregulated NCCRP-1 with the loss of UBC-association in the chronic pressure ulcer is unclear.  
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NCCRP-1 and MMGT1 are genes present in the individual targeted core and stress 
regulator networks that contain UBC with a connecting network edge to ELAVL1 (ELAV 
(embryonic lethal, abnormal vision, Drosophila)-like 1(Hu antigen R))`. ELAVL1 is an RNA-
binding Protein that can promote RNA stability and influence transcription [309][310]. In stress-
treated and untreated cells ELAVL1 was shown to elevate some key target genes including p53 
which is part of a cellular transcriptional core regulatory unit [220].  Additionally ELAVL1 has 
been shown to stabilize many target mRNA's including those that encode stress-response and 
proliferative proteins including CDKN1A, Cyclins, iNOS, HIF1-α, VEGF, SIRT1, TNFα, BCL-
2, and DUSP-1 [311-317]. Heat shock studies showed that  transcriptional levels of HuR mRNA 
did not change in heat shock but rather that HuR protein stability was reduced [318]. Ubiquitin 
has been associated with ELAVL1 through the following observations: ELAVL1 was 
ubiquitinated in vitro and CHK2 kinase protected against ELAVL1 loss while proteosome 
inhibition led to an increase in ELAVL1 abundance [318].  
 In opposition to heat shock, ELAVL1 is downregulated in the chronic pressure ulcers     
(-2.4 Fold, p <0.001). This observation demonstrates specificity of ELAVL1 to heat shock 
responses and suggests that the wound environment is not undergoing a heat shock response. 
Targeted network analysis demonstrated a UBC association with ELAVL1 to the normal skin 
control proteins. ELAVL1 was not associated with any of the targeted core and stress regulator 
analyses of the 8 UBC associated proteins unique to chronic pressure ulcers and the 
transcriptional downregulation of ELAVL1 in chronic pressure ulcers may indicate its 
background role of this protein in normal skin.  
95 
MMGT1 is a gene that encodes a protein that is located in the Golgi complex and post-
Golgi vesicles. MMGT1 is known to transport strontium, iron, cobalt and copper [319]. 
Originally MMGT1 was thought to contribute to the regulation of magnesium- dependent 
enzymes that are involved in protein assembly and glycosylation [320]. Later, an integrated 
mapping strategy identified MMGT1 as part of the mEMC (mammalian Endoplasmic Reticulum 
Membrane Complex) which was one of six ERAD related functional modules that perform 
substrate recognition, dislocation, extraction, ubiquitination and proteosomal degradation [321]. 
The function of the mEMC is currently unknown although MMGT1 is present in the normal skin 
suggesting that the MMGT1 association with UBC/ELAVL1 is present in the normal skin and 
may be important for the functioning of normal ion transport and ERAD in the skin [321]. 
MMGT was slightly downregulated in the CPU (-1.16, p<0.001). ). Individual analysis of 
MMGT1 in relation to targeted core and stress regulators demonstrated MMGT1-ELAVL1 and 
MMGT1-UBC associations. However, MMGT1 is not associated with UBC in the CPU. 
Together these observations suggest transcriptional rather than UBC regulation of these genes in 
the chronic wound.  
 BEX4 is localized to the x-chromosome and is located between BEX1 and BEX2 and is 
notably expressed uniformly and at high levels and is found in the nucleus and cytoplasm 
(passive diffusion) in the heart, skeletal muscle, liver and kidney [322]. BEX4 expression in 
primary cell lines correlated with promoter methylation. It was shown that overexpression of 
BEX4 induced apoptosis in cancer cell lines [323] and that loss of  BEX4 was associated with 
deregulation of c-Myc activity, cyclin D1 levels resulting in cellular transformation [323]. Thus, 
these data implicated BEX4 as a tumor regulatory protein [323]. Individual analysis of BEX4 in 
relation to targeted core and stress regulators demonstrated an association with UBC that was 
indirectly affected by BRCA-1, CDKN1A, p53 and CDK2. TP53 is the common gene between 
these networks. BEX4 is downregulated (-1.39, p<0.001) in the chronic pressure as compared to 
the skin control (Table 5.). Together with the loss of association with UBC this gene also 
demonstrates transcriptional regulation with concomitant loss of UBC association. Both the 
presence and role of BEX4 and the BEX4-ELAVL1-UBC associations in both the normal skin 
control and the chronic pressure ulcers of SCI patients are unknown.  
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KPRP is a newly identified epidermal protein associated with the upper granular 
components of the cornified layer of the skin [324]. KPRP was previously identified in a 
specialized high throughput screen of the transcriptome of importance for epidermal barrier 
function [325]. Independently, KPRP was suggested to be a marker of stratified 
epithelia(granular layer) with a potential role in keratinocytic development [324].  This gene was 
expressed in both the skin control and chronic pressure ulcers in SCI patients (Table 5.). 
Individual analysis of KPRP in relation to targeted core and stress regulators demonstrated a 
direct association with CDK2 and indirect associations with p53, cJUN, EGFR, GSK3B, PI3K, 
HoxB1 through Histone 3 (Figure 2). A protein-protein association of CDK2 and KPRP was 
 identified in embryonic stem cells [326] and may indicate the involvement of stem cells in the 
skin. Additionally, it was noted that the expression of HoxB1 is associated with regulation of the 
retinoblastoma tumor suppressor [227] while association with Histone 3 implies epigenetic 
regulation. These observations demonstrate that KPRP is intricately associated both directly and 
indirectly with these key core regulators. It is unknown whether loss of the UBC association in 
the chronic pressure ulcer adversely affects the UBC-related effects on KPRP present in the 
normal skin. 
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 THUMPD1 was identified through a genetic linkage and T-cell gene expression 
study [327]. THUMPD1 was mapped to a peak linkage within Tsi1 (T-cell secretion of 
interleukin) and this locus is associated with high expression levels of  IL-4 [327]. Thus, 
THUMPD1 (Thump domain containing 1) is an immunity related gene that is transcriptionally 
downregulated between the normal skin control and the Chronic Pressure Ulcers (Table 5.). This 
gene was proposed to be a key regulator of in-vitro Th2 differentiation at the Tsi1 locus and was 
found to be over expressed in BALB/c mice as compared with B6 mice [327]. Interestingly, 
RNA message stability was proposed as a possible mechanism for the differential expression of 
THUMPD1 between the two mice strains and it was noted that message stability could be due to 
a deletion of an AU-rich element in the BALB/c mouse which would predispose this message for 
quick degradation if it were present. Targeted core and stress regulator network analysis 
demonstrated that THUMPD1 is associated only with UBC thus an association with the core 
transcriptional regulators has not yet been shown. THUMPD1 is markedly downregulated (-4.93, 
p<0.01) in the chronic pressure as compared to the skin control (Table 5.). Together with the loss 
of association with UBC this gene also demonstrates transcriptional regulation. The role of the 
UBC-THUMPD1 association with immune responses in the CPUs is unknown.  
  DEF8 (Differentially Expressed in FDCP 8 Homolog) is also, associated with 
immune functions in the normal skin control. DEF8 was identified as one of 32 genes 
overexpressed in the Cd14+ unstimulated peripheral blood monocytic control cells from hyper-
immunoglobulin (IgE) syndrome (HIES) patient [328]. HIES is characterized by staphylococcal 
infection, eczema and high levels of IgE [329][330].  HIES is a multi-syndrome disease and it 
was suggested that the molecule (s) responsible for the disease would need to affect various 
biological functions rather than only Th1 or Th2 T-cell responses [328]. Targeted core and stress 
regulator network analysis demonstrated that DEF8 is associated only with UBC demonstrating 
that an association between DEF8 and the core transcriptional regulators has not yet been shown. 
This suggests regulation by UBC rather than stress regulators in the normal skin. DEF8 is 
downregulated (-1.16, p<0.001) in the chronic pressure as compared to the skin control (Table 
5.). Together with the loss of association with UBC this gene also demonstrates transcriptional 
regulation with concomitant loss of UBC association. The precise role of the UBC-THUMPD1 
association with immune responses in the CPUs is unknown.  
98 
 Nitrosylation is a form of oxidative stress. Transnitrosylation is known to affect 3000 
proteins and is well associated with nitric oxide synthases which can result in apoptotic 
programmed cell death [331] [332]. RILPL1 (Rab interacting lysosomal protein-like 1 is 
associated with cell survival and cell death and it is known to compete with SIAH  (a RING 
finger E3 Ligase) in binding nitrosylated GAPDH generated from diverse cellular stimuli [333]. 
S-Nitrosylation was shown to eliminate catalytic activity of GAPDH cause binding of GAPDH 
to Siah (a RING finger E3 ligase)[334].  Binding of GAPDH to SIAH uncovers a nuclear 
localization signal located in Siah and causes nuclear translocation of the GAPDH/Siah complex 
to the nucleus where it binds to p300/CBP and affects acetylation of master transcriptional 
 regulators including p53 [334]. RILPL1 is a protein that is also S-nitrosylated and was found to 
competitively bind to Siah and prevent the nuclear translocation of GAPDH. RILPL1 is not 
transcriptionally regulated in the CPUs (Table 5.) while GAPDH is upregulated (1.93, p<0.001) 
fold in the CPU. This may indicate an increased sensitivity of the cell toward apoptosis from 
oxidative stress in the CPU wound edges. 
 Individual analysis of RILPL1 in relation to targeted core and stress regulators 
demonstrate an association of RILPL1 with SQSTM1 (p62) showing the significance of the 
RILPL1 and SQSTM1 association. This association was discovered in the delineation of the 
response of the toll like receptors to viral infections [335]. Individual stress network analysis 
demonstrated that RILPL1 is affected indirectly by both NFkB and AP-1 through SQSTM1.  
RILPL1 is located in the normal skin control and is associated with ubiquitin. This association is 
lost in the CPU and may indicate a different biological effect of RILPL1. 
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 SECISBP2L (SECIS binding protein 2-like) is involved in selenocyteine incorporation 
into selenoproteins in humans [336]. Selenoproteins have an essential physiological role in 
oxidative stress defense [337]. Selenium deficiency, and numerous mutations in selenoproteins 
and selenoenzymes have been linked to various disorders of the endocrine, central nervous, 
muscular, cardiovascular, and immune systems in man [338] SBP2-like (SECISBP2L) protein is 
a homologue of SBP2 [336]. Survey of eukaryotic SECIS binding proteins (SBPs) found that 
SBP2 and SECISBP2L are paralogues in vertebrates [336]. SECISBP2L is the sole SBP in some 
invertebrates including sea urchins, sea squirts, and an annelid worm in the genus Capitella 
[339]. Conservation between SBP2L in vertebrates, invertebrates and mammals suggested role 
for SBP2L in the post-transcriptional regulation of selenoprotein expression [339].  
  SECISBP2L and SBP2 were found to be different in their ability to incorporate 
selenocysteine and SBP2 or SECISBP2L immunoprecipitation experiments showed specific 
association of selenoprotein mRNAs (GPX1 and GPX4) with both SBP2 and SECISBP2L [336]. 
The results showed that mammalian cells have at least two selenoprotein mRNP populations and 
suggested a role for SECISBP2L in the post-transcriptional regulation of selenoprotein 
expression [336]. SECISBP2L was associated with UBC in the normal skin controls but was 
transcriptionally downregulated (-1.39 Fold, p<0.001) in the chronic pressure ulcer tissue (Table 
5.). Individual analysis of SECISBP2L in relation to targeted core and stress regulators 
demonstrated an indirect association of SECISBP2L with core stress regulators. Together with 
the loss of association with UBC this gene also demonstrates transcriptional regulation with 
concomitant loss of UBC association. The association with UBC in both the normal skin control 
and the chronic pressure ulcers of SCI patients are unknown.  
 
Summary 
100 
 Chronic pressure ulcers are notoriously hard to heal. One main problem is the fact that 
these develop over bony prominences due to pressure, moisture and shear forces [340]. Ulcer 
formation over the bony prominence then predisposes the affected individual to microbial 
infection and secondary health problems such as osteomyelitis [341]. Skin substitutes have been 
evaluated and are sometimes utilized on the legs and feet where they have some success but 
information is generally lacking and it is known that these are not very effective where bony 
prominences exist. Additionally, evaluation of CPU in SCI patients has indicated that all phases 
of wound healing, with the exception of collagen breakdown, are adversely affected in these 
 patients with hypoxia and inflammation playing central roles in the detrimental, anti-healing 
environment present in the CPUs of these patients [342].  
 In this study we have utilized microarray and IPA®Network analysis to probe wound 
edges in spinal cord injury patients with chronic pressure ulcers and compared these results with 
results obtained from normal skin controls in the same patients. Whole genome analysis 
combined with IPA®Network analysis yielded one, comparable network between the chronic 
pressure ulcers and the normal skin control that was of the highest statistical significance. This 
network was UBC centered and differed in 8 genes from normal skin (Table 5).  
 The central position of UBC is critical because ubiquitin is the central common 
denominator for both the chronic pressure ulcer and the normal skin. Ubiquitination is a post-
translational modification that can function in different ways but includes proteosomal, 
lysosomal and autophagosomal degradation [257]. Ubiquitination can also affect signal 
transduction and activating/deactivating functions associated with genes [305]. Investigation of 
the each gene within the normal skin and chronic pressure ulcer networks demonstrated that each 
gene was associated with a particular biofunction (Table 6).  
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 Table 6: Functions of Genes Associated with UBC in Normal Skin Controls and Chronic 
Pressure Ulcers of Spinal Cord Injury Patients   
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 The eight genes identified as unique to chronic pressure ulcers represent treatable targets 
of chronic pressure ulcers. Stress gene related network analysis was utilized to probe the nature 
of the chronic pressure ulcers for the association of transcriptional regulators known to be 
directed by androstene hormones. Core transcriptional regulators associated with the androstene 
hormone directed stress response can be seen underlying the association with UBAP1 (Figure 
 103 
19) which was a gene associated with endosomal trafficking and degradation of membrane 
proteins essential to wound healing. This demonstrates the link between ubiquitin-proteosomal 
activity and the core regulators transcriptionally affected by androstene hormones.  
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER 5: General Discussion and Overall Conclusion 
 
 
 
 
 
 The study of the cortical adrenal hormones has been intense over the last 70 years. The 
discovery that hydrocortisone alleviated symptoms of rheumatoid arthritis was a major 
breakthrough and resulted in the belief that adrenal cortical steroids had anti-inflammatory 
properties. Subsequently, the discovery and intense study of β androstene hormones (primarily 
DHEA, 17α-AED, 17β-AED and 17β-AET) demonstrated that a plethora of debilitating humans 
diseases could be positively affected through the administration of these β androstene hormones. 
Variable results obtained through different studies have yielded some skepticism about the utility 
of these hormones despite large volumes of data supporting the positive effects obtained after 
administration of these adrenal hormones.  
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 There have been few major insights into the cellular and molecular mechanism of action 
of these androstene hormones in the last 20 years. The overall rationale of these studies was to 
further advance the knowledge of the cellular and molecular actions related to these androstene 
hormones utilizing traditional biological (reporter assays and microarray) and advanced systems 
biology methods (network analysis) with emphasis placed primarily on 17α-AED and 17β-AED. 
This represents the first time ever that this approach has been utilized.  Furthermore, an 
additional goal of these studies was to utilize network analysis to determine if the β androstene 
hormones might have utility in their treatment of chronic pressure ulcers. Together, these studies 
test the hypothesis that the β androstene hormones will achieve their cellular and molecular 
 effects through actions that do not necessarily include the nuclear receptors. 
 Many studies have shown that application of β-androstene hormones resulted in an 
interaction between different members of the nuclear receptors (androgen, estrogen receptor 
alpha and estrogen receptor beta). Despite the ability of the androstene hormones to activate the 
androgen and estrogen receptors, they have also been shown to elicit their biological effects in 
cell lines devoid of the androgen and estrogen receptors. This is the first study which compares 
the action of DHEA and its derivatives directly on the human androgen, estrogen, and 
glucocorticoid receptors.  
 The inherent androgenicity and estrogenicity of these hormones has been controversial 
and biological activity (cell proliferation) has been attributed to androgenicity and estrogenicity 
of mainly DHEA and 17β-AED. These studies, for the first time, demonstrated the differences 
between DHEA, 17α-AED, 17β-AED and 17β-AET and demonstrated a decrease of 
androgenicity and estrogenicity that is on orders less than either testosterone or 17β-estradiol. 
The initial studies sought to characterize the ability of DHEA, 17α-AED, 17β-AED and 17β-
AET to both bind the receptor and activate transcription in a cellular constructs containing 
human nuclear receptors. Thus, these experiments would confirm prior reports and provide the 
necessary information on 17α-AED and 17β-AET in relation to 17β-AED, which is known to be 
a weak binder and activator, of the ESR1 and AR. Additionally, no information was currently 
available for β androstene hormones binding and activation of the human ESR2. 
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   The overall hypothesis of Chapter 1 was:  Androstene Hormones will bind and activate 
ESR1, ESR2, AR, and GR differently than their known ligands when compared concurrently on 
whole cell constructs. Once obtained, the androstene hormone activity could then be compared 
with the known ligands of the ERα, ERβ, AR or GR nuclear receptors. A second aim to this 
 hypothesis was to determine if DHEA, 17α-AED, 17β-AED and 17β-AET influence binding and 
activation of the glucocorticoid receptor when the receptor was activated with its known ligand 
which would demonstrate if androstene hormones would produce anti-glucocorticoid activity at 
the level of the human receptor.  
 The androstene hormones directly activated the ERα, ERβ and AR but at levels that were 
orders of magnitude less than estradiol and testosterone. These studies demonstrated that the β 
androstene hormones each produced unique, differential interactions and level of activation of 
these human nuclear receptors indicating that there may be additional factors involved. This 
result demonstrated that, at the receptor level, the binding and action of these hormones is 
different than 17β-estradiol and testosterone on the human ERα, ERβ and AR and their activity 
with these receptors may not be a requirement for their biological activity. Furthermore, these 
observations support the hypothesis that the biological effects of the androstene hormones are 
not primarily mediated through interaction with the human ERα, ERβ and AR. Consistent with 
these observations, androstene hormones have been shown to promulgate their biological effects 
when the estrogen and androgen receptors are not present. The results were consistent with prior 
studies and extended the knowledge of the β androstene hormone interactions with the human 
ERα, ERβ and AR.  
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 Metabolites of DHEA produced intracellularly [343], such as 17β-AED, 
Androstenedione, testosterone and dihydrotestosterone will cause activation and transactivation 
of ERα, ERβ and AR [344]. In Chapter 1 studies, DHEA did metabolize into 17β-AED and 
therefore the activity of DHEA was, at least in part, due to 17β-AED in the nuclear receptor 
assay cells, however, it was also demonstrated that, in these whole cell assay constructs, 17α-
AED, 17β-AED and 17β-AET were not transformed into any metabolites with the ability to bind 
 and transactivate the human nuclear receptors tested in Chapter 1. The results directly reflected 
only the  ability of 17α-AED, 17β-AED and 17β-AET to interact with these human nuclear 
receptors.  
 Activity of 17β-AED has been associated with anti-glucocorticoid activity. It was not 
known if these interactions occurred at the level of the receptor. Consequently, we pursued the 
anti-glucocorticoid activity of the androstene hormones.  17α-AED, 17β-AED and 17β-AET did 
not directly activate the GR and also did not inhibit the GR ligand, dexamethasone. Conversely, 
there was differential activity of all the receptors, evidenced only at supra-high levels of 
androstene hormone and dexamethasone, even in the presence of the AR and GR inhibitor: 
cyproterone.  These results extended the knowledge of the human GR receptor and demonstrated 
in this construct that at very high concentrations of agonist there is an indirect interaction that 
occurs outside the pocket of the human GR that affects the activation of the human GR. Thus, 
anti-glucocorticoid activity that is produced by androstene hormones is derived externally to the 
“active pocket” of the human GR.  
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 No androstene hormone initiated activation of the human GR receptor and there was a 
differential effect exhibited by DHEA, 17α-AED, 17β-AED and 17β-AET in the presence of 
dexamethasone. Together, these observations with the differential biological anti-glucocorticoid 
actions demonstrated by the androstene hormones indicate that the androstene hormones have a 
differential, indirect effect on the human GR at the receptor level and may further indicate that 
these hormones have the ability to modulate glucocorticoid activity. Further studies will need to 
be performed to examine the biological actions produced by androstene hormones that result in 
anti-glucocorticoid activity.  
  The androstene hormones are known to produce diametrically opposite biological effects. 
17α-AED is known to induce irreversible apoptosis in lymphoma cells (U937) and irreversible 
autophagy in T98G, U87MG, LN-Z308 and GBM6 Glioblastoma Multiforme cell lines. The 
chemically identical epimer of 17α-AED, 17β-AED, is known for protection against diverse 
stressors and promotes cell survival. The main biological effect (irreversible autophagy) of 17α-
AED is now known to occur through the ER stress receptor, PERK, and is propagated through 
eLF2α and CHOP (Gadd153) in Glioblastoma Multiforme cells. Studies ascribed a structural 
relationship with its biological activity to 17α-AED. It was shown in these studies that the 
hydroxyl group in the 3β position was dispensable in relation to biological activity but the 
hydroxyl group at the 17α-postion was critical for the biological activity. Thus overall, we 
demonstrate that the position of the hydroxyl group at the 17 position of 17β-AED, 17α-AED 
and 17β-AET determines and the hydroxyl group at 7 position influences the biological activity 
of these β-androstene hormones at the level of the ERα, ERβ, AR and GR receptors.  
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 In chapter 1 we demonstrated that the structure related to the hydroxyl located at 
positions 7 and 17 resulted in differential activation of a transcriptional reporter in whole cell 
constructs. 17α-AED and 17β-AED are chemically identical and only differ at the position of the 
hydroxyl at the 17 position with respect to the cycloperhydrophenanthrene ring of the hormone. 
Since 17α-AED and 17β-AED are chemically identical and the biological effects of 17α-AED 
and 17β-AED are opposing and the biological activity 17α-AED and 17β-AED is attributed to 
the hydroxyl group at the 17 position and because the biological actions associated with the 
irreversible cell death stimulated by 17α-AED is known, it was hypothesized that 17α-AED of 
T98G Glioblastoma Multiforme cells would cause the cells to stimulate gene transcription 
 resulting in irreversible cell death while 17β-AED treatment would stimulate gene transcription 
that would result in cell survival.  
 Thus, one aim of this hypothesis was to identify a transcriptional, cell-directed genetic 
program stimulated by 17α-AED that resulted in cell death while at the same time identifying the 
transcriptional cell-directed genetic program stimulated by 17β-AED that results in cell survival. 
Since androstene hormones are naturally produced in humans, this set of genes would also 
represent a core geneset that human cells utilize to either promote survival or death. Thus broad 
signal transduction microarray that contained 113 genes was performed on T98G Glioblastoma 
Multiforme cells that were treated with either 17α-AED or 17β-AED. It was determined that 
17α-AED or 17β-AED regulated 26 of 113 total genes by greater than one magnitude in opposite 
directions (17β-AED >5 fold and 17α-AED <5 Fold). These twenty six genes are presented in 
Chapter 2 and represent a specific, core set of genes involved in the transcriptional, cell-directed 
genetic program stimulated by 17α-AED or 17β-AED that results in cell death or survival 
respectively.  
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 The identification of the core set of genes regulated in an opposing fashion by 17α-AED 
and 17β-AED and aligned with the known biological results demonstrated that a transcriptional, 
cell-directed program for cell death and survival exists for these epimers through this common 
geneset. Thus, this led us to hypothesize that network analysis of this geneset could be utilized to 
elucidate how these genes were associated with each other thus advancing our understanding of  
the androstene hormone directed program of cellular life and death. The second aim of this study 
was to further advance the understanding of the known biological action of 17α-AED and 
delineate the action of 17β-AED. Together, these observations would advance our current 
knowledge of how 17α-AED or 17β-AED influence cell directed life and death decisions. 
  Network analysis was performed on the 26 member geneset. Network analysis was 
extremely useful as the network scores could be utilized for 2 important functions. First, 
networks (and thus gene groupings) could be ranked by most significant to least significant based 
on the number and associations of the genes (genes included together within networks are termed 
focus genes) within the network.  Second, the gene groups represent associations of how these 
genes may be organized biologically.  
 The overall results presented in Chapter 2 demonstrate that 17α-AED directs its actions 
through PERK, an endoplasmic reticulum stress receptor, while downregulating BRCA1, BCL2, 
GADD45, CDKN1A and IRF-1. In opposition, 17β-AED stimulated upregulation of BRCA1 and 
BCL2 with a concomitant upregulation of GADD45, CDKN1A and IRF-1. When upregulated 
together (Figure 13), this geneset implies that 17β-AED induces a program of DNA repair and 
growth control. Microarray and Network analysis also implicated the action of WNT1 and its 
subsequent action on GSK3β as key components to either stimulate or shut down the eukaryotic 
translation initiation factor elF2α and upregulate or downregulate the core transcription regulator 
p53. Furthermore, examination of the networks and the geneset provided evidence that AKT was 
differentially modulated by these epimers. Examination of the core transcriptional regulators 
demonstrated that p53 and RB/E2F core transcriptional units were implicated in the survival or 
cell death associated with 17α-AED or 17β-AED. 
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 Analysis of the genetic mutations that are common to Glioblastoma Multiforme and 
application to T98G cells demonstrated that mutations exist in components of the 
CDKN2A/MDM2/p53 axis, the PTEN and NF1 associated Ras/PI3K axis and the 
CDKN2A/CDK4/RB axis. It could be seen that 17α-AED affected these pathways through 
downregulation of the geneset while 17β-AED affected these pathways through upregulation of 
 the geneset. Importantly, 17α-AED or 17β-AED exerted their biological effects in the T98G 
Glioblastoma Multiforme cells despite the presence of mutations in the core transcriptional 
regulators.  
 Demonstration of the existing common geneset along with the results presented in 
Chapter 1 supports the idea that 17α-AED or 17β-AED exert their effects at least, in part, 
through an opposing biological action which is related to the structural stereochemistry of these 
two chemically identical hormones. The 26 gene set of common genes that are regulated in 
opposition by 17α-AED or 17β-AED exist and many of them are either known transcriptional 
master regulators or affect those regulators within the geneset. Through the use of 17α-AED or 
17β-AED, T98G Glioblastoma Multiforme cells, microarray and network analysis it was 
possible to demonstrate that an opposing biological action that includes transcriptional regulation 
of a set of influential biological regulators exists and is related to the structural stereochemistry 
of these two chemically identical hormones.  
 Core transcriptional regulators within the 17α-AED or 17β-AED common geneset can be 
associated with cell directed programs of cell cycle control, cell death, angiogenesis inhibition 
and metastasis or DNA Repair. It could be seen that 17α-AED achieved its effects through 
downregulation of core transcriptional regulators and deactivation of translation initiation 
resulting in cell death. Downregulation of the common geneset could be seen to augment the 
action of 17α-AED and thus expands the current knowledge of how this androstene hormone 
stimulates Glioblastoma Multiforme cells to direct cell death.  
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 In opposition, upregulation of the common geneset delineated how 17β-AED propagated 
its effects in Glioblastoma Multiforme cells. The upregulation of the common geneset suggests 
that 17β-AED propagates a cellular program of DNA repair and growth control (Chapter 3). 
 Finally, these observations along with the observations presented in Chapter 1 further support 
and strengthen the argument that while androstene hormone activity is influenced by ERα, ERβ, 
AR and GR these human nuclear receptors are not the primary arbiter of the cellular and 
molecular activity of 17α-AED, 17β-AED and 17β-AED. Importantly, the 26 member geneset 
identified how 17α-AED and 17β-AED stimulate cellular life and death decisions even in the 
presence of genomic mutation and instability. 
 Chronic pressure ulcers in spinal cord injury patients represent a multi-factorial, hard-to-
treat condition that develops over time in patients with limited mobility. The environment of the 
chronic wound is one of infection, hypoxia, repetitive ischemia/reperfusion, and an altered 
cellular and stress response.  Once a chronic pressure ulcer has formed it becomes a significant 
health burden both to patients and the healthcare system. These wounds are particularly difficult 
since spinal cord injury patients have limited mobility and the ulcers usually form from shear 
pressures located on bony prominences.  
 Since, microarray and network analysis was useful in delineating the action of 17α-AED 
or 17β-AED, this technique was again utilized to briefly analyze chronic pressure ulcer wound 
edges and normal skin. 17α-AED and 17β-AED exert their effects through an ER stress sensing 
action and their biological effects are promulgated through a common geneset containing master 
transcriptional regulators. The master transcriptional regulators within the 17α-AED or 17β-AED 
common geneset can be associated with cell directed programs of cell cycle control, cell death, 
angiogenesis inhibition and metastasis or DNA Repair. These properties may indicate an 
application for 17α-AED and/or 17β-AED in the treatment of chronic pressure ulcers.  
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 Thus, we hypothesized that the master transcriptional regulators regulated by 17α-AED 
or 17β-AED stimulated cells may underlie the altered cellular and systemic responses seen in the 
 chronic wound environment. The primary aim was to identify the primary significant difference 
between the chronic wound and the normal skin and then apply targeted network analysis of 
these genes with the 17α-AED and 17β-AED common geneset that contains master 
transcriptional regulators. Association of these regulators with the significant differences within 
the wound indicates an application for androstene hormones. 
 The analysis revealed that networks were "rewired" in the chronic wound edges probably 
reflecting the multi-factorial state known to be present in these wounds. For simplicity, a 
complete review (Chapter 4) was performed only on network number 1 for two main reasons 1) 
Network 1 is the most statistically significant network. 2) Network 1 contained mainly similar 
genes between the chronic pressure and the normal skin. The primary observation is that 
ubiquitin C is the central molecule of network 1 in both the chronic wound and the normal skin. 
 Review of the genes revealed that eight genes were different between the chronic 
pressure ulcer and normal skin in network 1. Functional comparison demonstrated that the genes 
associated with the chronic pressure ulcer do indeed reflect the multi-factorial state of the 
chronic pressure ulcer while loss of the eight UBC-associated genes in the normal skin implies a 
loss of skin functionality associated with theses genes. CERCAM and LMF2 were associated 
with abnormal skin barrier function, abnormal collagen synthesis due to lack of glycosylation 
and leukocyte transmigration. An important observation is that 17β-AED will significantly 
increase CD11b/CD18 (MAC-1) after radiation [99]. Since CERCAM was shown to bind to 
CD11b then the implication is that 17β-AED or 17β-AET would promote beneficial immune cell 
trafficking and processes in the stress altered environment of the chronic pressure ulcer.  
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 CLIP3 and SLC22A17 were related to cellular apoptosis while UBAP1 suggested 
lysosomal degradation of EGFR which was accompanied by a transcriptional decrease in EGFR t 
 while RNF24 and RNF145 represent E3 ligases involved in ubiquitination processes. Together, 
these processes suggest that the ubiquitin-proteosomal system may be the central factor in 
regulating the altered cellular and stress response of the chronic wound environment. The main 
observation is the loss of association of UBC with genes that regulate barrier function in, 
immunity and oxidative stress, in normal skin. 
 Targeted microarray analysis of the eight different genes demonstrated that p53, CDK2, 
SQSTM1 and UBC were active in the regulation of CERCAM. UBAP1 demonstrated a more 
complex interaction with the common geneset and the glucocorticoid receptor, EGR1, NAB2, 
GADD45 and BRCA1 were implicated in the regulation of EGFR, which is significantly 
downregulated and known to play a leading role in the cell survival and proliferation seen in 
normal wound healing. In addition, CLIP3 analysis added cJUN to the list of regulators 
associated with the eight UBC-associated genes that are present in the chronic pressure ulcer.   
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 Additionally, EGFR was associated with the presence of the glucocorticoid receptor 
(Figure 19). The glucocorticoid receptor is known to counteract the activity of the EGFR [346]. 
Furthermore, the glucocorticoid receptor is known to predispose individuals with chronic stress 
to mental anxiety,  immune deficiency, inflammatory dysregulation and impair wound healing 
[347][348][349][112]. It has been shown prior that androstene hormones can counteract the 
glucocorticoid receptor [73] and stress-impaired wound healing [112][170].  It is demonstrated 
here that the androstene hormones interact indirectly and have applicability to the treatment of 
chronic wounds since it is demonstrated here that the androstene hormones influence the human 
GR indirectly, influence biological activity of the human GR and a subset of the 26 genes known 
to be transcriptionally regulated by androstene hormones (core regulators) are associated with the 
UBC-associated genes unique to the chronic pressure ulcers. 
  A critical observation is that NCCRP-1, CERCAM, ThumpD1, DEF8, CLIP3, RNF24, 
SLC22A17, UBAP1 were genes in both the normal and chronic pressure ulcer skin that represent 
activity of the innate immune system. Thus, NCCRP-1, ThumpD1, and DEF8 loss of association 
with UBC in the chronic pressure ulcer represents a loss of normal innate immune function while 
the association of CERCAM, CLIP3, RNF24, SLC22A17 and UBAP1 represent an abnormal 
innate immune function in non-healing skin. Since abnormal innate immune functions are 
associated with non-healing pressure ulcers then these genes can be seen as primary targets of 
therapies targeting chronic pressure ulcers.  
Three main observations demonstrate that 17β-AED and 17β-AET may be effective 
therapeutics in the chronic wound environment. First, these hormones are known to increase 
effective innate immune processes in the presence of stress demonstrated by modulation of 
innate immune cytokines and effective cellular responses. Second, these hormones are known to 
counteract the effects of the glucocorticoid receptor also through the modulation of innate 
immune cytokines and cellular responses. Third, 17β-AED is now known to initiate a cellular 
program of DNA repair, growth control and immunity through the modulation of transcriptional 
regulators.  
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 The androstene hormones are known to be beneficial to stress-related delayed wound 
healing and provide the means to discover how core transcriptional regulators can themselves be 
regulated to influence the eight genes uniquely associated with the ubiquitin-proteosomal system 
in the chronic wounds. Thus, counteracting the action of the GCR receptor and initiating an 
effective innate immune response may lead to new and effective therapies in the treatment of 
chronic pressure ulcers. The genes identified in this analysis may represent treatment biomarkers 
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which can guide treatments aimed at improve healing or the effectiveness of existing therapies 
such as application of skin substitutes. 
 Future studies will need to be performed to elucidating the structure-function relationship 
of the androstene hormones to further expand on what is now known. Elucidation of interactions 
between the core regulators and UBC will be critical in understanding how the androstene 
hormones influence broad biological regulatory processes, including protein production 
(transcription and translation), modification (phosphorylation, acetylation, ubiquitination etc.) 
and degradation (proteosomal, lysosomal and autophagic). Understanding how the 
transcriptional, cell-directed programs stimulated by androstene hormones influence broad 
biological regulatory processes such as innate immunity or counteract the action of 
glucocorticoids will illuminate how these adrenal cortical steroids achieve their remarkable 
biological effects and may result in treatments with applicability to many complex, hard-to-treat 
or currently untreatable human conditions.
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Normal Skin, Network 1, UBC-associated Gene Information 
     
Symbol Synonym(s) Entrez Gene Illumina ID/ Human 
  Name Accession Entrez 
    Gene ID 
     
KPRP 1110001M24Rik,  Keratinocyte ILMN_1780649/ 448834 
 AA589586,  proline-rich   NM_001025231.1  
 C1orf45 protein   
     
NCCRP1 1190020J12Rik,  non-specific  ILMN_1713397/ 342897 
 FBXO50, cytotoxic cell  NM_001001414.1  
 Gm163, receptor protein    
 RGD1305932 1 homolog    
  (zebrafish)   
     
THUMPD1 6330575P11Rik THUMP  ILMN_2108339/ 55623 
  domain  NM_017736.3  
  containing 1   
     
DEF8 AI449518,  differentially ILMN_1767509/ 54849 
 D8Ertd713e,  expressed in  NM_207514.1  
 FLJ20186 FDCP 8    
  homolog    
  (mouse)   
     
MMGT1 9630048L06Rik,  membrane  ILMN_1776216/ 93380 
 BC032271, magnesium  NM_173470.1  
 EMC5,  transporter 1   
 RGD1566339,              
 RP11-274K13.3,     
 TMEM32    
  
 
Normal Skin, Network 1, UBC-associated Gene Information (Continued) 
 
Symbol Synonym(s) Entrez Gene Illumina ID/ Human 
  Name Accession Entrez 
    Gene ID 
      
SECISBP2L 3110001I20Rik,  SECIS  ILMN_1784333/ 9728 
 AI504340, binding  NM_024077.2  
 C630011I23, protein 2-like   
 RGD1559930,    
 RP23-367K9.1,    
 SLAN    
     
BEX4 BEXL1,  Brain ILMN_1804798/ 56271 
 FLJ10097,  Expressed NM_001006937.1  
 RP23-1A3.7,  X-Linked 4   
 RP4-635G19.2    
     
RILPL1 2900002H16Rik,  Rab  ILMN_1805643/ 353116 
 6330559I19Rik,  interacting NM_178314.2  
 GOSPEL,  lysosomal   
 MNCb-2440,  interacting   
 RGD1307973,  protein-like 1   
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Chronic Pressure Ulcer Skin Edge, Network 1, UBC-associated Gene Information 
     
Symbol Synonym Entrez Gene Illumina ID/ Human 
  Name Accession Entrez 
    Gene ID 
     
CERCAM 2600006K01RIK,  cerebral  ILMN_1750563/ 51148 
 AL024097, endothelial  NM_016174.3  
 CEECAM1, cell    
 GLT25D3, adhesion    
 RP11-339B21.2, molecule   
 RP23-443G7.3    
     
LMF2 AI451006,  lipase  ILMN_1716056/ 91289 
 RGD1306274,  maturation  NM_033200.1  
 TMEM153,  factor 2   
 TMEM112B    
     
CLIP3 1500005P14Rik,  CAP-GLY  ILMN_1789733/ 25999 
 AI844915,  domain NM_015526.1  
 CLIPR-59, containing   
 RGD1306245,  linker    
 RSNL1 protein 3   
      
SLC22A17 24p3R,  solute  ILMN_1653200/ 51310 
 1700094C23Rik, carrier  NM_016609.3  
 AU041908, family 22,    
 AW555662, member 17   
 BOCT, BOIT,    
 hBOIT, Lcn2 receptor,    
 mBOCT, NGALR2,    
 NGALR3, NGALR,     
 RBOCT    
  
 
Chronic Pressure Ulcer Skin Edge, Network 1, UBC-associated Gene Information 
(Continued) 
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Symbol Synonym Entrez Gene Illumina ID/ Human 
  Name Accession Entrez 
    Gene ID 
UBAP1 2700092A01Rik,  ubiquitin  ILMN_1807596/ 51271 
 NAG20,  associated  NM_016525.3  
 RP11-571F15.1, protein 1   
 RP23-328E6.5,     
 UAP, UBAP    
     
RNF24 2810473M14RIK, ring finger  ILMN_1717809/ 11237 
 4930505A13Rik,  protein 24 NM_007219.2  
 AI317164,     
 C86507,     
 D2Ertd504e,     
 G1L,     
 RP23-387C21.6    
     
RNF145 3732413I11RIK,  ring finger  ILMN_1710906/ 153830 
 FLJ31951,  protein 145 NM_144726.1  
 RGD1309561,     
 RP23-103H9.1,     
 TMRF1    
     
C8orf76 9130401M01Rik,  chromosome  ILMN_1742074/ 84933 
 AI849328, 8 open  NM_032847.1  
 RGD1310852 reading    
  frame 76   
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